CZ2001798A3 - Use of thia- or oxazolidinone derivatives for preparing a medicament for therapy or prevention of ulcer diseases - Google Patents

Abstract

The use of oxa or thiazolidinone derivs. of formula (I) and their optical isomers and salts for the treatment of ulcers or angina is new. In (I), W = S or O and X = NR3; or X = S or O and W = NR3; R3 = H, 1-6 C alkyl or aryl-1-4 C alkyl; R4, R5 = H, 1-6 C alkyl, aryl 1-4 C alkyl, or phenyl or Het both opt. substd. by 1-6 C alkyl, NH2 or mono- or di- 1-6 C alkylamino; Het = 5-6 membered heterocyclyl contg. 1-3 O, N or S; R6 = H, 1-6 C alkyl or aryl 1-4 C alkyl; A = 2-6 C alkylene opt. substd. by carboxy, 1-6 C alkoxycarbonyl, or aryloxycarbonyl; aryl = 6-10 C aryl opt. substd. by 1-6 C alkyl, 1-6 C alkoxy, OH, halo, NH2 or mono- or di- 1-6 C alkylamino.

Description

Use of thia- or oxazolidinone derivatives for the manufacture of a medicament for the treatment or prevention of ulcer diseases

Technical field

The present invention relates to the use of optically active thiazolidinone derivatives having an excellent collateral vascular stretch effect and anti-angina pectoris effect for the preparation of a composition for the prevention or therapy of angina pectoris containing them as an active ingredient, preventive or therapeutic methods for angina pectoris, comprising administering a pharmacologically effective amount thereof, or a process for preparing a mammal; or a composition for preventing or treating an ulcer disease comprising thia- or oxazolidinone derivatives as an active ingredient, or therapeutic methods for an ulcer disease, comprising administering to a mammal a pharmacologically effective amount thereof.

BACKGROUND OF THE INVENTION

Currently, nitroglycerin is the most commonly used clinically as a therapeutic agent for cardiovascular diseases, especially angina pectoris. However, nitroglycerin readily undergoes the effect of an initial release of passage through its deficiency that the duration of its action is short. At the same time, headaches, dizziness and acceleration of heart rate due to lowering of blood pressure appear as side effects. For these reasons, a prolonged-acting therapeutic agent is required for angina pectoris that does not clinically undergo the initial release of passage.

• · ······· · ·

SUMMARY OF THE INVENTION

A compound has been found as a means to solve the above problem having a thia- or oxazolidinone skeleton, for example a compound of formula A

O.

(AND)

C-A-ONO2

AND

Rd (where R _a , R i, R e are hydrogen, etc., A is C 8 -C 8 -alkylene and Y is oxygen or sulfur) (for example, Japanese Unexamined Patent Publication (KOKAI) No. Hei 5-213910). However, the anti-ulcer action of these compounds is not yet known.

Further research has been conducted and it has been found that compounds having an optically active thiazolidinone skeleton have an excellent collateral vascular expansion effect that is prolonged and exhibits fewer side effects, the compounds being useful as a preventive or therapeutic agent for angina pectoris (especially as therapeutic agent for angina and the compounds have excellent stability, enhancing the present invention. Furthermore, the inventors have investigated the pharmacological effects of compounds having a thia- or oxazolidinone skeleton and have also found that these compounds have an excellent anti-ulcer effect and that the compounds are useful as a preventive or therapeutic agent for ulcer disease (especially as a therapeutic agent for ulcer disease).

The present invention provides optically active thiazolidinone derivatives, a composition for the prevention or therapy of angina, containing them as an active ingredient, their use for the manufacture of a pharmaceutical composition for the prevention or therapy of angina, preventive or

2a_ a therapeutic method for angina pectoris comprising administering to said mammal a pharmacologically effective amount thereof or a process for preparing therefrom; or a composition for the prevention or therapy of an ulcer containing thia- or oxazolidinone derivatives as an active ingredient, their use for the manufacture of pharmaceutical preparations for the prevention or therapy of an ulcer or a preventive or a therapeutic method. for ulcer disease, comprising administering to a mammal a pharmacologically effective amount thereof.

The optically active thiazolidinone derivatives of the invention have the general formula I:

O (l)

wherein R 1 represents a hydrogen atom, a C 1 -C 2 -alkyl group, a phenyl group, a substituted phenyl group (the substituent means a C 1 -C 4 -alkyl group, a C 1 -C 4 -alkoxy group or a halogen), a phenyl-C 1 -C 2 -alkyl group or a substituted phenyl group -C 1 -C 2 -alkyl (phenyl is substituted with C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or halogen);

R 6 represents a C 1 -C 8 -alkyl group; and n is 1 or 2.

The thia- or oxazolidinone derivatives which are the active ingredients of the preventive agent or the therapeutic agent for the ulcer disease have the general formula II:

(II)

wherein W represents a sulfur atom or an oxygen atom and X represents a group -N (R 6) - or

X is S or O and W is -N (R 6) -;

r 3 represents a hydrogen atom, a C 1 -C 6 -alkyl group or an aryl-C 1 -C 6 -alkyl group;

and R 6 may be the same or different and represent a hydrogen atom, a C 1 -C 6 -alkyl group, an aryl-C 1 -C 4 -alkyl group, an aryl group, a five- or six-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, which may preferably be fused to a benzene ring or a 5- or 6-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms which may be preferably substituted and fused to a benzene ring (the substituent means a C 1 -C 8 -alkyl group, an amino group, a mono-C 1 -C 4 -alkylamino group or a di-C 1 -C 8 -alkylamino group);

R ⁶ represents a hydrogen atom, a C 1 -C 8 -alkyl group or an aryl-C 1 -C 4 -alkyl group;

A represents a C 2 -C 8 -alkylene group or a substituted C 2 -C 8 -alkylene group (the substituent means a carboxyl group, a C 1 -C 8 -alkoxycarbonyl group or an aryloxycarbonyl group); and aryl represents a C8-C8-aryl group or a substituted C8-C8-aryl group (the substituent means a C1-C8-alkyl group, a C1-C8-alkoxy group, a hydroxy group, a halogen, an amino group, a mono-C1-C8- group alkylamino, di-C 1 -C 8 -alkylamino or nitro).

The C 1 -C 4 -alkyl of R 1, etc., or the C 1 -C 4 -alkoxy alkyl group contained in R 1 may contain, for example, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, isobutyl and t-butyl, preferably

C 1 -C 3 -alkyl, more preferably C 1 -C 2 -alkyl and especially preferably methyl.

··· ·····························································

The halogen atom contained in R1 may include, for example, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and preferably a fluorine atom and a chlorine atom.

The phenyl-C 1 -C 2 -alkyl group of R 1 may preferably contain a benzyl group or a phenethyl group, and more preferably a benzyl group.

The C 1 -C 8 -alkyl group of R 1 may include, for example, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, isobutyl, t-butyl, pentyl and hexyl, preferably C 1 -C 6 alkyl, more preferably methyl, ethyl a propyl, isopropyl, butyl or isobutyl group, and more preferably a methyl, propyl, butyl or isobutyl group, and particularly preferably a methyl group.

C 1 -C 8 -alkyl from R 1, r 4, r 5, r 6 _and td. or an alkyl group of a C 1 -C 8 -alkoxy group or a C 1 -C 8 -alkylamino group contained in R 1, A etc. may contain the above group, preferably a C 1 -C 2 -alkyl group, more preferably a C 1 -C 2 -alkyl group and particularly preferably a methyl group.

The aryl of aryl-Cj-C ^ alkyl of R, R4, R5 _and R6 _m ay include the group described below and the alkyl group may comprise an upper group and may include for example benzyl, phenethyl, 2-phenylpropyl, 3-phenylpropyl, 4-phenylbutyl, diphenylmethyl, 1-naphthylmethyl and 2-naphthylmethyl, preferably phenyl- (C 1 -C 4 -alkyl), even more preferably benzyl or phenyl, and particularly preferably benzyl.

The aryl group of R 4 and R 6 or the aryl group of the aryloxycarbonyl group contained in A may contain an upper group and preferably a phenyl group.

The halogen or substituent of the aryl group of R 4 and R 6 may contain an upper group and preferably a fluorine atom or a chlorine atom.

A 5- or 6-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms which may be selected from the group consisting of: Preferably condensed with a benzene ring, may include, for example, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, indolyl, quinolyl and quinazolinyl, preferably a furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or pyridyl group, even more preferably a furyl, thienyl or pyridyl group, and particularly preferably a furyl or thienyl group.

The alkylene group of the C2-C8-alkylene group of A may comprise, for example, ethylene, methylethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene, preferably C2-C4-alkylene, and particularly preferably ethylene or methylene.

Those of the compounds of formula II which contain a carboxyl group or a phenolic group can form salts with bases. Such salts may include, for example, an alkali metal salt such as lithium, sodium or potassium, an alkaline earth metal salt such as barium or calcium, a salt with other metals such as magnesium and aluminum, an organic amine salt such as dicyclohexylamine and a basic amino acid salt such as is lysine and arginine and preferably an alkali metal salt. At the same time, the compound of formula (II) containing amino or alkylamino groups can form acid salts. Such salts may include, for example, a salt with an inorganic acid such as hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid and carbonic acid, a carboxylic acid salt such as acetic acid, fumaric acid, maleic acid, oxalic acid, malonic acid, succinic acid, citric acid, malic acid and benzoic acid, a salt with a sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid and a salt with an acidic amino acid such as glutamic acid and aspartic acid and preferably a salt with hydrochloric acid or carboxylic acid.

Further, the invention includes hydrates of a compound of formula I and, in cases where an asymmetric carbon exists in the molecule of a compound of formula II, the invention includes racemic modification and an optically active agent, and also comprises a compound of formula II or hydrates of a salt thereof.

· ♦ «·« «« «« • ·· ·· ···

The compound of formula I contained in the compound of formula II also has an excellent anti-ulcer effect.

The compound of formula I preferably comprises:

1) a compound in which _R 1 is a hydrogen atom, a C 1 -C 4 -alkyl group, a phenyl group, a substituted phenyl group (a substituent is a methyl group, a methoxy group, a fluorine or chlorine atom), a benzyl group, a substituted benzyl group a group, a methoxy group, a fluorine or chlorine atom), a phenethyl group or a substituted phenethyl group (the substituent being a methyl group, a methoxy group, a fluorine or chlorine atom);

2) a compound wherein R 'is hydrogen, methyl, 4-methoxyphenyl or benzyl;

3) a compound wherein R 1 is hydrogen;

4) a compound in which the C 1 -C 4 alkyl group is;

5) a compound in which the group is methyl, ethyl, propyl, isopropyl, butyl or isobutyl;

6) a compound in which the group is methyl, propyl, butyl or isobutyl;

7) a compound in which the methyl group is a

8) a compound wherein n is 1.

Also preferred is a combination of compounds selected at the discretion of the group consisting of 1) -3), 4) -7) and 8, which includes, for example, the following compounds

9) a compound in which _R 1 is a hydrogen atom, a C 1 -C 2 -alkyl group, a phenyl group, a substituted phenyl group (a substituent being a methyl group, a methoxy group, a fluorine or chlorine atom), a benzyl group, a substituted benzyl group a group, a methoxy group, a fluorine or chlorine atom, a phenethyl group or a substituted phenethyl group (the substituent being a methyl group, a methoxy group, a fluorine or chlorine atom); is C1-C4 alkyl; and n is 1;

10) a compound in which R1 is a hydrogen atom, a methyl group, a 4-methoxyphenyl group or a benzyl group; is methyl, ethyl, propyl, isopropyl, butyl, isobutyl; and n is 1;

11) a compound wherein R 1 is hydrogen; R 6 is methyl, propyl, butyl or isobutyl; and n is 1 and

12) a compound wherein R1 is hydrogen; and R 6 is a methyl group.

The compound of formula (II) preferably comprises

13) a compound in which a hydrogen atom is a C8-C12-alkyl group, a benzyl group or a phenethyl group;

14) a compound in which the hydrogen atom is a methyl group or a benzyl group;

15) a compound in which W is sulfur or oxygen and X is -N (r 3) - (where is hydrogen) or X is sulfur and W is -N (R 3) - (where is hydrogen) ;

16) a compound wherein W is sulfur or oxygen and X is -N (R 6) - (where H is hydrogen);

17) a compound in which and may be the same or different and each of them is a hydrogen atom, a C 1 -C 4 alkyl group, a phenyl-C 1 -C 4 -alkyl group, a substituted phenyl-C 1 -C 4 -alkyl group (the phenyl group is substituted) C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, hydroxy, halogen or nitro), naphthylmethyl, phenyl, substituted phenyl (the substituent is C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, hydroxy , halogen or nitro), naphthyl or unsubstituted furyl or C 1 -C 4 -alkyl substituted furyl.

9999, thienyl, pyridyl, oxazolyl, thiazolyl, isoxazolyl or isothiazolyl;

18) a compound in which R ⁴ and R 6 may be the same or different and each is a hydrogen atom, a methyl group, a benzyl group, a substituted benzyl group (the substituent being a methyl group, a methoxy group, a hydroxy group, a fluorine or chlorine atom) phenethyl, substituted phenethyl (substituent is methyl, methoxy, hydroxy, fluoro or chloro), phenyl, substituted phenyl (substituent is methyl, methoxy, hydroxy, fluoro or chloro), furyl, thienyl or pyridyl;

19) a compound wherein R ⁴ is a hydrogen atom, a methyl group, a benzyl group, a substituted benzyl group (the substituent is methyl, methoxy or hydroxy), a phenyl group, a substituted phenyl group (the substituent is methyl, methoxy or hydroxy); and R 8 is hydrogen;

20) a compound wherein R ⁴ is hydrogen, methyl, benzyl, phenyl or methoxyphenyl and R 6 is hydrogen;

21) a compound wherein R ⁴ is hydrogen, methyl, benzyl, or 4-methoxyphenyl, and R 6 is hydrogen;

22) a compound wherein R ⁴ is hydrogen and R 6 is hydrogen;

23) a compound wherein R 1 is hydrogen, C 1 -C 4 -alkyl, benzyl or phenethyl;

24) a compound wherein R 1 is hydrogen, methyl or benzyl;

25) a compound wherein hydrogen is;

26) a compound in which A is a C 2 -C 4 -alkylene group, a carboxy-C 2 -C 4 -alkylene group or a C 1 -C 4 -alkoxycarbonyl-C 2 -C 4 -alkylene group;

27) a compound wherein A is a C 2 -C 4 -alkylene group; or · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·· ·

28) a compound in which A is ethylene or 1-methylethylene.

Also preferred is a combination of compounds selected at the discretion of the group consisting of 13) -16), 17) -22), 23) -25) and 26) -28 and includes, for example, the following compounds

29) a compound wherein R 1 is hydrogen, C 1 -C 4 -alkyl, benzyl, or phenethyl;

r 4 and r 5 may be the same or different and each is a hydrogen atom, a C 1 -C 4 -alkyl group, a phenyl-C 1 -C 2 -alkyl group, a substituted phenyl-C 1 -C 4 -alkyl group (the phenyl group is substituted with a C 6 -C 4 -alkyl group) alkyl, C1-C4-alkoxy, hydroxy, halogen or nitro), naphthylmethyl, phenyl, substituted phenyl (substituent is C1-C4-alkyl, C1-C4-alkoxy, hydroxy, halogen or nitro), naphthyl or unsubstituted furyl or C 1 -C 4 -alkyl substituted furyl, thienyl, pyridyl, oxazolyl, thiazolyl, isoxazolyl or isothiazolyl;

R ⁶ is hydrogen, C 1 -C 4 -alkyl, benzyl or phenethyl; and

A is C2-C4-alkylene, carboxy-C2-C4-alkylene or C1-C4-alkoxycarbonyl-C2-C4-alkylene,

30) a compound in which a hydrogen atom is a methyl group or a benzyl group;

R 4 and R 5 may be the same or different and each is a hydrogen atom, a methyl group, a benzyl group, a substituted benzyl group (a substituent is methyl, methoxy, hydroxy, a fluorine or chlorine atom), a phenethyl group, a substituted phenethyl group methyl, methoxy, hydroxy, fluoro or chloro), phenyl, substituted phenyl (the substituent is 4). Methyl, methoxy, hydroxy, fluorine or chlorine), furyl, thienyl or pyridyl;

R 6 is hydrogen, methyl or benzyl; and

A is C2-C4-alkylene;

31) a compound in which W is sulfur or oxygen and X is -N (R 3) - (wherein

R 6 is hydrogen) or X is sulfur and W is -N (R 6) - (where R is hydrogen);

R ⁴ is a hydrogen atom, a methyl group, a benzyl group, a substituted benzyl group (the substituent is methyl, methoxy or hydroxy), a phenyl group or a substituted phenyl group (the substituent is methyl, methoxy or hydroxy);

R 5 is hydrogen;

R 6 is hydrogen; and

A is C2-C4-alkylene;

32) a compound wherein W is sulfur or oxygen and X is -N (R 6) - (wherein R 3 is hydrogen);

R ⁴ is hydrogen, methyl, benzyl, phenyl or methoxyphenyl;

r 5 is hydrogen;

is hydrogen; and

A is C2-C4-alkylene;

33) a compound wherein W is sulfur and X is -N (R 6) - (where hydrogen is);

· * * · · · · · · · · · · · · · · · · · · · · · · ·

R 4 is hydrogen, methyl, benzyl or 4-methoxyphenyl;

r 5 is hydrogen;

R 6 is hydrogen; and

A is ethylene or 1-methylethylene; or

34) a compound wherein W is sulfur and X is -N (R ² ) - (wherein R ² is hydrogen);

R 6 is hydrogen;

is hydrogen;

R 6 is hydrogen; and

A is ethylene or 1-methylethylene.

The preferred compound of formula I can be specifically shown in the examples in Table 1.

(AND)

CONH ^'(s)' (CH ₂₎ n ONO 2

Table 1

compound C. R ¹ R ² n 1-1 H Me 1 1-2 Me Me 1 1-3 Et Me 1 1-4 Ph Me 1

1-5 4-Me-Ph Me 1 1-6 4-MeO-Ph Me 1 1-7 4-F-Ph Me 1 1-8 4-Cl-Ph Me 1 1-9 Bz Me 1 1-10 4-Me-Bz Me 1 1-11 4-MeO-Bz Me 1 1-12 4-F-Bz Me 1 1-13 4-Cl-Bz Me 1 1-14 CH ₂ CH ₂ Ph Me 1 1-15 H Et 1 1-16 Me Et 1 1-17 Ph Et 1 1-18 4-Me-Ph Et 1 1-19 4-MeO-Ph Et 1 1-20 4-F-Ph Et 1 1-21 4-Cl-Ph Et 1 1-22 Bz Et 1 1-23 4-Me-Bz Et 1 1-24 4-MeO-Bz Et 1 1-25 4-F-Bz Et 1 1-26 4-Cl-Bz Et 1 1-27 H Ex 1 1-28 Me Ex 1 1-29 Ph Ex 1 1-30 4-Me-Ph Ex 1 1-31 4-MeO-Ph Ex 1 1-32 4-F-Ph Ex 1

14 1-33 4-Cl-Ph Ex 1 1-34 Bz Ex 1 1-35 4-Me-Bz Ex 1 1-36 4-MeO-Bz Ex 1 1-37 4-F-Bz Ex 1 1-38 4-Cl-Bz Ex 1 1-39 H Me 2 1-40 Me Me 2 1-41 Ph Me 2 1-42 4-Me-Ph Me 2 1-43 4-MeO-Ph Me 2 1-44 4-F-Ph Me 2 1-45 4-Cl-Ph Me 2 1-46 Bz Me 2 1-47 4-Me-Bz Me 2 1-48 4-MeO-Bz Me 2 1-49 4-F-Bz Me 2 1-50 4-Cl-Bz Me 2 1-51 H Et 2 1-52 Me Et 2 1-53 Ph Et 2 1-54 4-Me-Ph Et 2 1-55 4-MeO-Ph Et 2 1-56 Bz Et 2 1-57 4-Me-Bz Et 2 1-58 4-MeO-Bz Et 2 1-59 H _Ex 1 1-60 Me _Ex 1

··············

1-61 Ph Pr ¹ 1 1-62 4-Me-Ph Pr ' 1 1-63 4-MeO-Ph Pr ' 1 1-64 4-F-Ph At 1 1-65 4-Cl-Ph Pr · 1 1-66 Bz At 1 1-67 4-Me-Bz Pr ' 1 1-68 4-MeO-Bz Pr ' 1 1-69 4-F-Bz Pr ' 1 1-70 4-Cl-Bz Pr ' 1 1-71 H Bu 1 1-72 Me Bu 1 1-73 Ph Bu 1 1-74 4-Me-Ph Bu 1 1-75 4-MeO-Ph Bu 1 1-76 4-F-Ph Bu 1 1-77 4-Cl-Ph Bu 1 1-78 Bz Bu 1 1-79 4-Me-Bz Bu 1 1-80 4-MeO-Bz Bu 1 1-81 4-F-Bz Bu 1 1-82 4-Cl-Bz Bu 1 1-83 H Bu ' 1 1-84 Me Bu ' 1 1-85 Ph Bu ' 1 1-86 4-Me-Ph Bu ' 1 1-87 4-MeO-Ph Bu ' 1

· · · · · · · · ·

16 1-88 4-F-Ph Bu * 1 1-89 4-Cl-Ph Bu * 1 1-90 Bz Bu * 1 1-91 4-Me-Bz Bu * 1 1-92 4-MeO-Bz Bu * 1 1-93 4-F-Bz Bu * 1 1-94 4-Cl-Bz Bu * 1 1-95 H Bu ^s 1 1-96 Me Bu ^s 1 1-97 Ph Bu ^s 1 1-98 4-Me-Ph Bu ^s 1 1-99 4-MeO-Ph Bu ^s 1 1-100 Bz Bu ^s 1 1-101 4-Me-Bz Bu ^s 1 1-102 4-MeO-Bz Bu ^s 1 1-103 H But 1 1-104 Me But 1 1-105 Ph But 1 1-106 4-Me-Ph But 1 1-107 4-MeO-Ph But 1 1-108 Bz But 1 1-109 4-Me-Bz Bu ¹ 1 1-110 4-MeO-Bz Bu ¹ 1 1-111 H Pn 1 1-112 Me Pn 1 1-113 Ph Pn 1

• ·

17 1-114 4-Me-Ph Pn 1 1-115 4-MeO-Ph Pn 1 1-116 Bz Pn 1 1-117 4-Me-Bz Pn 1 1-118 4-MeO-Bz Pn 1 1-119 H Hx 1 1-120 Me Hx 1 1-121 Ph Hx 1 1-122 4-Me-Ph Hx 1 1-123 4-MeO-Ph Hx 1 1-124 Bz Hx 1 1-125 4-Me-Bz Hx 1 1-126 4-MeO-Bz Hx 1 1-127 H Ex 2 1-128 Me Ex 2 1-129 Ph Ex 2 1-130 4-Me-Ph Ex 2 1-131 4-MeO-Ph Ex 2 1-132 Bz Ex 2 1-133 4-Me-Bz Ex 2 1-134 4-MeO-Bz Ex 2 1-135 H Pr · 2 1-136 Me Pr · 2 1-137 Ph Pr · 2 1-138 4-Me-Ph At 2 1-139 4-MeO-Ph Pr ’ 2 1-140 Bz Pr · 2 1-141 4-Me-Bz Pr · 2

• ·

1-142 4-MeO-Bz p _r l 2 1-143 H Bu 2 1-144 Me Bu 2 1-145 Ph Bu 2 1-146 4-Me-Ph Bu 2 1-147 4-MeO-Ph Bu 2 1-148 Bz Bu 2 1-149 4-Me-Bz Bu 2 1-150 4-MeO-Bz Bu 2 1-151 H Either 2 1-152 Me Either 2 1-153 Ph Either 2 1-154 4-Me-Ph Either 2 1-155 4-MeO-Ph Either 2 1-156 Bz Either 2 1-157 4-Me-Bz Either 2 1-158 4-MeO-Bz Either 2

In Table 1, abbreviations indicate the following groups:

Bz ... benzyl

Bu ... butyl

Bu ¹ ... isobutyl

Be ^with ... s-butyl

Bul t-butyl

Et ... ethyl

Hx ... hexyl

Me ... methyl «methyl φ φ φ φ φ methyl methyl methyl

Ph ... phenyl

...Η ... pentyl

Pr ... propyl

Pr ¹ ... isopropyl

In Table 1, preferred compounds of the numbers: 1-1, 1-2, 1-3, 1-6, 1-7, 1-9, 1-10, 1-11, 1-12, 1-13, 1- 14, 1-15, 1-27, 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, 1-36, 1-39, 1-40, 1-43, 1-59, 160, 1-71, 1-72, 1-73, 1-74, 1-75, 1-78, 1-80, 1-83, 1-84, 1-85, 1-87, 1-90, 1-92, 1-95, 1-103, 1111, 1-112, 1-116, 1-119, 1-120, 1-112, 1-124, 1-112, 1-143 and 1-151;

even more preferred are the compounds of numbers: 1-1,1-2, 1-3, 1-6,1-9, 1-10, 1-12, 1-14, 1-27, 1-28, 1-29, 1-31, 1-32, 1-33, 1-34, 1-36, 1-60, 1-71, 1-72, 1-73, 1-75, 1-78, 1-80, 1- 83, 1-84, 1-85, 187, 1-90, 1-92, 1-95, 1-103, 1-111, 1-112.1-116, 1-119.1-120, 1- 123.1-124, 1-127, 1-143 and 1151;

and particularly preferred are compounds of numbers:

Compound No. 1-1: (4R) -N - [(1S) -1-Methyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-1-carboxamide, Compound No. 1-2: (4R) - N - [(1S) -1-methyl-2-nitroxyethyl] -5-methyl-2-oxothiazolidin-4-ylcarboxamide, Compound No. 1-6: (4R) -N - [(1S) -1- methyl-2-nitroxyethyl] -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide, Compound No. 1-9: (4R) -N - [(1S) -1-methyl-2-nitroxyethyl 5-Benzyl-2-oxothiazolidin-4-yl-carboxamide, Compound No. 1-15: (4R) -N - [(1S) -1-ethyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl -carboxamide, compound no. 1-27: (4R) -N - [(1S) -1-propyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide, compound no. 1-28: (4R) N - [(1S) -1-propyl-2-nitroxyethyl] -5-methyl-2-oxothiazolidin-4-ylcarboxamide;

Compound No. 1-31: (4R) -N - [(1S) -1-Propyl-2-nitroxyethyl] -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide, Compound No. 1- 34: (4R) -N - [(1S) -1-Propyl-2-nitroxyethyl] -5-benzyl-2-oxothiazolidin-4-ylcarboxamide, Compound No. 1-71: (4R) -N- [ (1S) -1-Butyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide, Compound No. 1-72: (4R) -N - [(1S) -1-Butyl-2-nitroxyethyl] -5-Methyl-2-oxothiazolidin-4-yl-carboxamide, Compound No. 1-75: (4R) -N - [(1S) -1-Butyl-2-nitroxyethyl) -5- (4-methoxyphenyl) - 2-Oxothiazolidin-4-yl-carboxamide, Compound No. 1-78: (4R) -N - [(1S) -1-Butyl-2-nitroxyethyl] -5-benzyl-2-oxothiazolidin-4-yl-carboxamide , Compound No. 1-83: (4R) -N - [(1S) -1-Isobutyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide, Compound No. 1-84: (4R) -N - [(1S) -1-isobutyl-2-nitroxyethyl] -5-methyl-2-oxothiazolidin-4-ylcarboxamide, Compound No. 1-87: (4R) -N - [(1S) -1-isobutyl -2-Nitroxyethyl] -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide and Compound No. 1-90: (4R) -N - [(1S) -1-isobutyl-2-nitroxy] ethyl] -5-benzyl-2-oxothiazolidin-4-ylcarboxamide.

Preferred compounds of formula II are specifically listed in Table 2 and Table 3. The compounds of Table 2 and Table 3 have the general structural formulas II-1 and II-2, respectively.

(11-1)

(li-2)

CO-NA-ONO ₂

Table 2

Compound No. . R ³ R ⁴ R ⁵ R ⁶ AND xl 2-1 H H H H (CH ₂ ) ₂ with 2-2 Me H H H (CH ₂ ) ₂ with 2-3 Et H H H (CH ₂ ) ₂ with 2-4 PhCH ₂ H H H (CH ₂ ) ₂ with 2-5 H Me H H (CH ₂ ) ₂ with 2-6 H Et H H (CH ₂ ) ₂ with 2-7 H Ph H H (CH ₂ ) ₂ with 2-8 H 2-Thi H H (CH ₂ ) ₂ with 2-9 H 3-Thi H H (CH ₂ ) ₂ with Table 2-10 H 2-Fur H H (CH ₂ ) ₂ with 2-11 H 3-Fur H H (CH ₂ ) ₂ with 2-12 H 3-NO ₂ -Ph H H (CH ₂ ) ₂ with 2-13 H 4-Cl-Ph H H (CH ₂ ) ₂ with 2-14 H 4-MeO-Ph H H (CH ₂ ) ₂ with 2-15 H 4-Thiz H H (CH ₂ ) ₂ with 2-16 H 3-Pyr H H (CH ₂ ) ₂ with 2-17 H Me Me H (CH ₂ ) ₂ with 2-18 Me Me Me H (CH ₂ ) ₂ with 2-19 Me Me Me Me (CH ₂ ) ₂ with 2-20 Et Ph H H (CH ₂ ) ₃ with 2-21 Et Et H Me _{(CH2) 4} with

2-22 PhCH ₂ Me H Et (CH ₂ ) ₂ WITH 2-23 PhCH ₂ Ph H Ex _(CH2) 4 with 2-24 Bu H H H (CH ₂ ) ₂ with 2-25 H 1-Naph H H (CH ₂ ) ₂ with 2-26 H H H Me (CH ₂ ) ₂ with 2-27 H H H PhCH ₂ (CH ₂ ) ₂ with 2-28 H PhCH ₂ H H (CH ₂ ) ₂ with 2-29 PhCH ₂ H H H (CH ₂ ) ₃ with 2-30 H H H H CH (Me) CH ₂ with 2-31 H H H H CH ₂ CH (Me) with 2-32 H H H H (CH ₂ ) ₅ with 2-33 H H H H (CH ₂ ) ₆ with 2-34 H H H H (CH ₂ ) ₂ 0 2-35 Me H H H (CH ₂ ) ₂ 0 2-36 Et H H H (CH ₂ ) ₂ 0 2-37 PhCH ₂ H H H (CH ₂ ) 2 0 2-38 H Me H H (CH ₂ ) ₂ 0 2-39 H Et H H (CH ₂ ) ₂ 0 2-40 H Ph H H (CH ₂ ) ₂ 0 2-41 H 2-Thi H H (CH ₂ ) ₂ 0 2-42 H 3-Thi H H (CH ₂ ) ₂ 0 2-43 H 2-Fur H H (CH ₂ ) ₂ 0 2-44 H 3-Fur H H (CH ₂ ) ₂ 0 2-45 H 3-NO ₂ -Ph H H (CH ₂ ) ₂ 0 2-46 H 4-Cl-Ph H H (CH ₂ ) ₂ 0 2-47 H 4-MeO-Ph H H (CH ₂ ) ₂ 0

• ·

9

9 9

9 9 9

2-48 Η 4-Thiz H H (CH ₂ ) ₂ 0 2-49 Η 3-Pyr H H (ch ₂ ) ₂ 0 2-50 Η Me Me H (ch ₂ ) ₂ 0 2-51 Me Me Me H (CH ₂ ) ₂ 0 2-52 Me Me Me Me (ch ₂ ) ₂ 0 2-53 Et Ph H H (CH ₂ ) ₃ 0 2-54 Et Et H Me _{(CH2) 4} 0 2-55 PhCH ₂ Me H Et (CH ₂ ) ₂ 0 2-56 PhCH ₂ Ph H Ex _{(CH2) 4} 0 2-57 Bu H H H (CH ₂ ) ₂ 0 2-58 H 1-Naph H H (CH ₂ ) ₂ 0 2-59 H H H Me (CH ₂ ) ₂ 0 2-60 H H H PhCH ₂ (CH ₂ ) ₂ 0 2-61 H PhCH ₂ H H (CH ₂ ) ₂ 0 2-62 H H H H (CH ₂ ) 3 0 2-63 H H H H CH (Me) CH ₂ 0 2-64 H H H H CH ₂ CH (Me) 0 2-65 H H H H (CH ₂ ) ₅ 0 2-66 H H H H _{(CH2) 6} 0 2-67 H H H H _{(CH2) 4} with 2-68 H H H H (CH ₂ ) ₃ with 2-69 H 4-Me-CH ₂ Ph H H (CH ₂ ) ₂ with 2-70 H _4-MeO-CH2 Ph H H (CH ₂ ) ₂ with 2-71 H 4-F-CH ₂ Ph H H (CH ₂ ) ₂ with 2-72 H _4-Cl-CH2 Ph H H (CH ₂ ) ₂ with 2-73 H 4-OH-CH ₂ Ph H H (CH ₂ ) ₂ with

2-74 Η 4-Me-2Ph H H (CH ₂ ) 2 WITH 2-75 Η 4-F-Ph H H (CH ₂ ) 2 WITH 2-76 Η 4-OH-Ph H H (CH ₂ ) ₂ with 2-77 Η 4-Me-CH ₂ Ph H H (CH ₂ ) ₂ 0 2-78 Η _4-MeO-CH2 Ph H H (CH ₂ ) ₂ 0 2-79 Η 4-F-CH ₂ Ph H H (CH ₂ ) ₂ 0 2-80 Η _4-Cl-CH2 Ph H H (CH 2) 2 0 2-81 Η 4-OH-CH ₂ Ph H H _{(CH2) 4} 0 2-82 Η 4-Me-Ph H H _{(CH2) 4} 0 2-83 Η 4-F-Ph H H (CH ₂ ) ₂ 0 2-84 Η 4-OH-Ph H H _(CH2) 4 0 2-85 Η H H H _{(CH2) 4} 0 2-86 Η Me H H CH (Me) CH ₂ with 2-87 Η 3-Fur H H CH (Me) CH ₂ with 2-88 Η 4-MeO-Ph H H CH (Me) CH ₂ with 2-89 Η PhCH ₂ H H CH (Me) CH ₂ with 2-90 Η Me H H CH (Me) CH ₂ 0 2-91 Η 3-Fur H H CH (Me) CH ₂ 0 2-92 Η 4-MeO-Ph H H CH (Me) CH ₂ 0 2-93 Η PhCH ₂ H H CH (Me) CH ₂ 0

Table 3

Compound No. R ³ R ⁴ R ⁵ R6 AND χΐ 3-1 H H H H (CH ₂ ) ₂ with 3-2 Me H H H (CH ₂ ) ₂ with 3-3 Et H H H (CH ₂ ) ₂ with 3-4 PhCH ₂ H H H (CH ₂ ) ₂ with 3-5 H Me H H (CH ₂ ) ₂ with 3-6 H Et H H (CH ₂ ) ₂ with 3-7 H Ph H H (CH ₂ ) ₂ with 3-8 H 2-Thi H H (CH ₂ ) ₂ with 3-9 H 3-Thi H H (CH ₂ ) ₂ with 3-10 H 2-Fur H H (CH ₂ ) ₂ with 3-11 H 3-Fur H H (CH ₂ ) ₂ with 3-12 H 3-NO ₂ -Ph H H (CH ₂ ) ₂ with 3-13 H 4-Cl-Ph H H (CH ₂ ) ₂ with 3-14 H 4-MeO-Ph H H (CH ₂ ) ₂ with 3-15 H 4-Thiz H H (CH ₂ ) ₂ with 3-16 H 3-Pyr H H (CH ₂ ) ₂ with 3-17 H Me Me H (CH ₂ ) ₂ with 3-18 Me Me Me H (CH ₂ ) ₂ with 3-19 Me Me Me Me (CH ₂ ) ₂ with 3-20 Et Ph H H (CH ₂ ) ₂ with 3-21 Et Et H Me _{(CH2) 4} with 3-22 PhCH ₂ Me H Et (CH ₂ ) ₂ with

3-23 PhCH ₂ Ph H Ex _{(CH2) 4} with 3-24 Bu H H H (CH ₂ ) ₂ with 3-25 H 1-Naph H H (CH ₂ ) ₂ with 3-26 H H H Me (CH ₂ ) ₂ with 3-27 H H H PhCH ₂ (CH ₂ ) ₂ with 3-28 H PhCH ₂ H H (CH ₂ ) ₂ with 3-29 H H H H (CH ₂ ) ₃ with 3-30 H H H H CH (Me) CH ₂ with 3-31 H H H H CH ₂ CH (Me) with 3-32 H H H H (CH ₂ ) ₅ with 3-33 H H H H (CH ₂ ) ₆ with 3-34 H H H H (CH ₂ ) ₂ 0 3-35 Me H H H (CH ₂ ) ₂ 0 3-36 Et H H H (CH ₂ ) ₂ 0 3-37 PhCH ₂ H H H (CH ₂ ) ₂ 0 3-38 H Me H H (CH ₂ ) ₂ 0 3-39 H Et H H (CH ₂ ) ₂ 0 3-40 H Ph H H (CH ₂ ) ₂ 0 3-41 H 2-Thi H H (CH ₂ ) ₂ 0 3-42 H 3-Thi H H (CH ₂ ) ₂ 0 3-43 H 2-Fur H H (CH ₂ ) ₂ 0 3-44 H 3-Fur H H (CH ₂ ) ₂ 0 3-45 H 3-NO ₂ -Ph H H (CH ₂ ) ₂ 0 3-46 H 4-Cl-Ph H H (CH ₂ ) ₂ 0 3-47 H 4-MeO-Ph H H (CH ₂ ) ₂ 0 3-48 H 4-Thiz H H (CH ₂ ) ₂ 0

• · • φ

3-49 Η 3-Pyr H H (CH ₂ ) ₂ 0 3-50 Η Me Me H (CH ₂ ) ₂ 0 3-51 Me Me Me H (CH ₂ ) ₂ 0 3-52 Me Me Me Me (CH ₂ ) ₂ 0 3-53 Et Ph H H (CH ₂ ) 3 0 3-54 Et Et H Me _{(CH2) 4} 0 3-55 PhCH ₂ Me H Et (CH ₂ ) ₂ 0 3-56 PhCH ₂ Ph H Ex _{(CH2) 4} 0 3-57 Bu H H H (CH ₂ ) ₂ 0 3-58 H 1-Naph H H (CH ₂ ) ₂ 0 3-59 H H H Me (CH ₂ ) ₂ 0 3-60 H H H PhCH ₂ (CH ₂ ) ₂ 0 3-61 H PhCH ₂ H H (CH ₂ ) ₂ 0 3-62 H H H H (CH ₂ ) ₃ 0 3-63 H H H H CH (Me) CH ₂ 0 3-64 H H H H CH ₂ CH (Me) 0 3-65 H 4-Me-Ph H H (CH ₂ ) ₂ 0 3-66 H 4-Me-Ph H H (CH ₂ ) ₂ with 3-67 H 4-Me-CH ₂ Ph H H (CH ₂ ) ₂ with 3-68 H _4-MeO-CH2 Ph H H (CH ₂ ) ₂ with 3-69 H 4-F-CH ₂ Ph H H (CH ₂ ) ₂ with 3-70 H _4-Cl-CH2 Ph H H (CH ₂ ) ₂ with 3-71 H 4-OH-CH ₂ Ph II H (CH ₂ ) ₂ with 3-72 H 4-F-Ph H H (CH ₂ ) ₂ with 3-73 H 4-OH-Ph H H (ch ₂ ) ₂ with

3-74 H 4-Me-CH ₂ Ph H H (CH ₂ ) ₂ 0 3-75 H _4-MeO-CH2 Ph H H (CH ₂ ) ₂ 0 3-76 H 4-F-CH ₂ Ph H H (CH ₂ ) ₂ 0 3-77 H _4-Cl-CH2 Ph H H (CH ₂ ) ₂ 0 3-78 H 4-OH-CH ₂ Ph H H (CH ₂ ) ₂ 0 3-79 H 4-F-Ph H H (CH ₂ ) ₂ 0 3-80 H 4-OH-Ph H H (CH ₂ ) ₂ 0 3-81 H H H H _{(CH2) 4} with 3-82 H H H H _{(CH2) 4} 0 3-83 H Me H H CH (Me) CH ₂ with 3-84 H 3-Fur H H CH (Me) CH ₂ with 3-85 H 4-MeO-Ph H H CH (Me) CH ₂ with 3-86 H PhCH ₂ H H CH (Me) CH ₂ with 3-87 H Me H H CH (Me) CH ₂ 0 3-88 H 3-Fur H H CH (Me) CH ₂ 0 3-89 H 4-MeO-Ph H H CH (Me) CH ₂ 0 3-90 H PhCH ₂ H H CH (Me) CH ₂ 0

In Tables 2 and 3, the abbreviations indicate the following groups.

Bu ... butyl

Et ... ethyl

Fur ... furyl

Me ... methyl

Naph ... diesel 1 «V 9 ·« «

Ph ... phenyl

Pr ... propyl

Fart ... pyridyl

Th ... thienyl

Thiz ... thiazolyl

In the above tables, compounds of the numbers: 2-1, 2-2, 2-5, 2-7, 2-8, 2-9, 2-10, 2-11, 2-12, 2-13, 2 are preferred. -14, 2-16, 2-17, 2-25, 2-26, 2-28, 2-31, 2-31, 2-34, 2-35, 2-38, 2-40, 241, 2 -42, 2-43, 2-44, 2-47, 2-61, 2-63, 2-67, 2-68, 2-69, 2-70, 2-71, 2-72, 2-73 , 2-74, 2-75, 2-76, 2-77, 2-78, 2-79, 2-80, 2-81, 2-83, 2-84, 2-85, 2 -86.2-87.2-88.2-89.2-90.2-91, 2-92,293, 3-1, 3-5, 3-7, 3-14, 3-30, 3 -34, 3-38, 3-40, 3-47, 3-65, 3-66, 3-68, 3-68, 3-69, 3-70, 3-71, 372, 3-73, 3 -83, 3-84, 3-85,3-86, 3-87, 3-88, 3-89 and 3-90;

even more preferred are the compounds of the numbers: 2-1, 2-2, 2-5, 2-7, 2-8, 2-14, 2-25, 2-28, 2-30, 2-34, 2-38, 2-41, 2-44, 2-47, 2-61, 2-63, 2-69, 2-70, 2-74, 2-78, 2-86, 2-88, 2-89, 2- 90, 2-91, 2-92, 293, 3-1, 3-7, 3-14, 3-30, 3-66, 3-67, 3-68, and 3-85;

and particularly preferred are compounds:

Compound No. 2-1: N- (2-Nitroxyethyl) -2-oxothiazolidin-4-yl-carboxamide, Compound No. 2-5: N- (2-Nitroxyethyl) -5-methyl-2-oxothiazolidin-4- yl-carboxamide, compound No. 2-14: N- (2-nitroxyethyl) -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide, compound No. 2-28: N- (2-nitroxyethyl) ) -5-Benzyl-2-oxothiazolidin-4-yl-carboxamide, Compound No. 2-30: N- (1-methyl-2-nitroxyethyl) -2-oxothiazolidin-4-yl-carboxamide, Compound No. 2- 34: N- (2-Nitroxyethyl) -2-oxoxazolidin-4-yl-carboxamide, Compound No. 2-44: N- (2-Nitroxyethyl) -5- (3-furyl) -2-oxoxazolidin-4-yl -carboxamide, compound No. 2-61: N- (2-nitroxyethyl) -5-benzyl-2-oxoxazolidin-4-yl-carboxamide, compound No. 2-63: N- (1-methyl-2-nitroxyethyl) -2-oxoxazolidin-4-yl-carboxamide, Compound No. 2-86: N- (1-methyl-2-nitroxyethyl) -5-methyl-2-oxothiazolidin-4-yl-carboxamide • to ··· · To · ····· · · To to to to to to to to to to to to to to to to to to to to to to to to to to to Compound No. 2-88: N- (1-Methyl-2-nitroxyethyl) -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide, Compound No. 2-89: N- (1-Methyl) 2-Nitroxyethyl) -5-benzyl-2-oxothiazolidin-4-yl-carboxamide, Compound No. 2-91: N- (1-methyl-2-nitroxyethyl) -5- (3-furyl) -2-oxoxazolidine -4-yl-carboxamide, compound No. 2-93: N- (1-methyl-2-nitroxyethyl) -5-benzyl-2-oxoxazolidin-4-yl-carboxamide, compound No. 3-1: N- ( 2-Nitroxyethyl) -2-oxothiazolidin-5-yl-carboxamide, Compound No. 3-14: N- (2-nitroxyethyl) -4- (4-methoxyphenyl) -2-oxothiazolidin-5-yl-carboxamide, Compound No. 3-14 3-30: N- (1-methyl-2-nitroxyethyl) -2-oxothiazolidin-5-ylcarboxamide and Compound No. 3-85: N- (1-methyl-2-nitroxyethyl) -4- (4 (methoxyphenyl) -2-oxothiazolidin-5-ylcarboxamide.

The compound of the present invention having the formula (I) is readily prepared by the following methods.

······························

Method A

(IV) step A1

(AND)

CONH ^{'(s) x} (CH ₂₎ n ONO ₂

Method B

(VI)

(AND)

CONH '(S) \ CH ₂ ) _n - ONO ₂ · · · · · · · · · · · · · · · · · · · ·

Method C

(IN)

stepCl ^{R 5} x R ¹⁰ o2

YR 1 (R)!

R ⁸ HN ^ CONH ^/ S ^x (CH ₂ ) _n -OH step C2 (VIII) step C3 ·

(IX)

In the above formulas, R1, R2 and n have the same meanings as defined above, R1 represents a mercapto protecting group and R1 represents an amino protecting group.

The mercapto protecting group is not particularly limited as is known in the art of synthetic organic chemistry and preferably comprises a trisubstituted silyl group having a substituent selected from the group consisting of C 1 -C 4 -alkyl, phenyl and phenyl substituted with C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or halogen, benzyl, benzyl substituted with C 1 -C 4 alkyl, C 1 -C 4 -alkoxy or halogen, benzyloxycarbonyl, benzyloxy carbonyl substituted with C 1 -C 2 -alkyl, C 1 -C 2 -alkoxy or halogen, t-butyl or t-butoxycarbonyl, more preferably trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, phenyldimethylsilyl, methoxybenzyl, dimethoxybenzyl, dimethoxybenzyloxycarbonyloxy, carbonylbenzyloxycarbonyloxy, or even more preferably a t-butyldimethylsilyl group

4-methoxybenzyl, 4-methoxybenzyloxycarbonyl or t-butoxycarbonyl, and particularly preferably t-butoxycarbonyl.

The amino protecting group is not particularly limited as is known in the art of synthetic organic chemistry and preferably comprises a tri substituted silyl group having a substituent selected from the group consisting of C 1 -C 2 -alkyl, phenyl and phenyl substituted by C 1 -C 2 -alkyl , C1-C4-alkoxy or halogen, benzyl, benzyl substituted by C1-C2-alkyl,

C 1 -C 4 -alkoxy or halogen, benzyloxycarbonyl, benzyloxycarbonyl substituted with C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or halogen, t-butyl or t-butoxycarbonyl, more preferably trimethyl silyl, triethylsilyl, t-butyldimethylsilyl, phenyldimethylsilyl, methoxybenzyl, dimethoxybenzyl, methoxybenzyloxycarbonyl, dimethoxybenzyloxycarbonyl or t-butoxycarbonyl, more preferably t-butyldimethylsilyl,

4-methoxybenzyl, 4-methoxybenzyloxycarbonyl or t-butoxycarbonyl, and particularly preferably t-butoxycarbonyl.

Method A is a process for preparing a compound of formula (I).

In step A1, a compound of formula I is prepared and the step is carried out by reacting a compound of formula III or by reacting its derivatives (acid halides, mixed acid anhydrides or active esters) with a compound of formula IV or an acid addition salt thereof. (E.g. mineral acid salts such as hydrochlorides, nitrates or sulphates) in an inert solvent and is carried out, for example, by the acid halide method, the mixed acid anhydride method, the active ester method, or condensation method.

The acid halide method is carried out by reacting a compound of formula III with a halogenating agent (e.g., thionyl dichloride, oxalyl chloride, phosphorus pentachloride, etc.) in an inert solvent to prepare the acid halide and reacting the acid halide with a compound of formula IV or an acid addition salt thereof solvent in the presence or absence of a base.

The base useful herein may include, for example, organic amines such as triethylamine, N-methylmorpholine, pyridine, and 4-dimethylamidopyridine; alkali metal hydrogencarbonates such as sodium hydrogencarbonate and potassium hydrogencarbonate; alkali metal carbonates such as sodium carbonate and potassium carbonate, and preferably organic amines.

The inert solvent useful herein is not particularly limited insofar as it does not affect the reaction and may include, for example, hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane and carbon tetrachloride; ethers such as ether, tetrahydrofuran and dioxane; ketones such as acetone; amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidone and hexamethylphosphoramide; and sulfoxides such as dimethysulfoxide and preferably hydrocarbons, halogenated hydrocarbons, ethers or amides.

The reaction temperature varies depending on the starting materials III and IV, the type of solvent, etc., and the reaction temperatures of both reactions, both the reaction of the halogenating agent with the compound of formula III and the reaction of the acid halide with the compound of formula IV are usually -20C to 150C. Preferably, the reaction temperature for the first reaction is -10 ° C to 50 ° C and for the second reaction 0 ° C to 100 ° C. The reaction time varies depending on the reaction temperature, etc., and the reaction time for both reactions is usually 15 minutes to 24 hours (preferably 30 ° C). minutes to 16 hours).

The mixed acid anhydride method is carried out by reacting a C 1 -C 8 -alkyl halocarbonate, di-C 1 -C 8 -alkylcyanophosphoric acid or di-C 8 -C 10 -arylphosphoryl azide with a compound of formula III to prepare a mixed acid anhydride and reacting the resulting mixed acid anhydride with a compound of Formula IV or an acid addition salt thereof.

· «·» · ♦ ♦ · · · · · · · · · · · · · · · · · ·

The reaction for the preparation of the mixed acid anhydride is carried out by reacting a C 1 -C 8 -alkyl halocarbonate such as methyl chlorocarbonate, ethyl chlorocarbonate, isobutyl chlorocarbonate and hexyl chlorocarbonate (preferably ethyl chlorocarbonate or isobutyl chlorocarbonate), preferably di-C 1 -C 8 diethyl cyanophosphoric acid) or di-C8-C10-arylphosphoryl azide such as diphenylphosphoryl azide, di (p-nitrophenyl) phosphoryl azide and dinaphthylphosphoryl azide (preferably diphenylphosphoryl azide) with a compound of formula III, preferably in an inert solvent in the presence of a base.

The base and inert solvent used herein are similar to those used in the acid halide method.

The reaction temperature varies depending on the starting material III, the type of solvent, etc., and is usually -20 ° C to 50 ° C (preferably 0 ° C to 30 ° C). The reaction time varies depending on the reaction temperature, etc., and is usually 15 minutes to 24 hours (preferably 30 minutes to 16 hours).

The reaction of the mixed acid anhydride with the compound of formula (IV) or an acid addition salt thereof is preferably carried out in an inert solvent in the presence or absence of a base. The base used and the inert solvent used herein are similar to those used in the acid halide method.

The reaction temperature varies depending on the starting material IV, the type of solvent, etc., and is usually -20 ° C to 100 ° C (preferably -10 ° C to 50 ° C). The reaction time varies depending on the reaction temperature, etc., and is usually 15 minutes to 24 hours (preferably 30 minutes to 16 hours).

Where dialkyl cyanophosphoric acid or diarylphosphoryl azide is used, this method may be carried out by reacting a compound of formula III with a compound of formula IV directly in the presence of a base.

The active ester method may be carried out by reacting a compound of formula III with an active esterifying agent (e.g., an N-hydroxy compound such as N-hydroxysuccinimide and N-hydroxybenzotriazole and the like) in the presence of a condensing agent (e.g. dicyclohexylcarbodiimide, carbonyldiimidazole etc.) to prepare the active ester. and reacting the active ester with a compound of formula III or an acid addition salt thereof.

• ·

The reaction to prepare the active ester is preferably carried out in an inert solvent, and the inert solvent used herein is similar to that of the acid halide method.

The reaction temperature varies depending on the starting materials III and IV, the type of solvent, etc., the reaction temperature for the active esterification reaction is usually -20 ° C to 50 ° C (preferably -10 ° C to 30 ° C), and the reaction temperature for reaction of the active ester compound. the compound of formula IV is generally -20 ° C to 50 ° C (preferably -10 ° C to 30 ° C). The reaction time varies depending on the reaction temperature, etc., and the reaction time for both reactions is usually 15 minutes to 24 hours (preferably 30 minutes to 16 hours).

The coupling method can be carried out by reacting a compound of formula III with a compound of formula IV or an acid addition salt thereof directly in the presence of a condensing agent (e.g. dicyclohexylcarbodiimide, carbonyldiimidazole, 1- (N, N-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and the like). is performed in a similar manner to the reaction to prepare the active ester.

After completion of the reaction, the desired compound of these reactions is captured from the reaction mixture by conventional means. For example, the desired compound from these reactions can be obtained by appropriately separating the insoluble matter by filtration and collecting the precipitated crystals by filtration; or by appropriately separating the insoluble matter by filtration, appropriately neutralizing, distilling off the solvent, adding water to the reaction mixture, extracting the mixture with a water-insoluble organic solvent such as ethyl acetate, drying the organic layer and evaporating the extraction solvent. If desired, the compound thus obtained can be further purified by conventional methods, for example, recrystallization, column chromatography and the like.

The starting compound of formula (III) for Method A is known or readily prepared according to known methods or methods similar to these [e.g. Tetrahedron, 45, 7459 (1989), J. Am. Chem. Soc., 79, 5203 (1957), J. Am. Chem. Soc., 111, 6354 (1989), etc.].

Method B is another method for preparing a compound of Formula I.

In step B1 a compound of formula VI is prepared and the step is carried out by reacting a compound of formula III or a reactive derivative thereof with a compound of formula

V, in an inert solvent. This step is carried out, for example, by the halide acid method, the mixed acid anhydride method, the active ester method or the condensation method, and is carried out in the same manner as step A1.

· · »» ··· · · · ·

In Step B2, a compound of Formula I is prepared and the step is carried out by reacting a compound of Formula VI with a nitrating agent in the absence or presence of an inert solvent.

The nitrating agent useful herein may include, for example, fuming nitric acid, nitrite tetrafluoroborate, thionyl chloride of nitric acid, thionic nitric acid, and nitrite tetrafluoroborate, and preferably fuming nitric acid, nitrite tetrafluoroborate or thionyl chloride of nitric acid.

The inert solvent useful herein is not particularly limited insofar as it does not affect the reaction and may include, for example, hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane and carbon tetrachloride; ethers such as ether, tetrahydrofuran and dioxane; ketones such as acetone; nitriles such as acetonitrile; amides such as Ν, Ν-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidone and hexamethylphosphoramide; and sulfoxides such as dimethyl sulfoxide, preferably halogenated hydrocarbons, ethers or nitriles, and particularly preferably nitriles.

The reaction temperature varies depending on the starting material VI, the type of nitrating agent, etc., and is usually -20 ° C to 50 ° C, and preferably room temperature. The reaction time varies depending on the reaction temperature, etc., and is usually 30 minutes to 24 hours (preferably 1 hour to 10 hours).

A compound of formula I is also prepared by reacting a compound of formula V with a sulfonating agent (e.g., C 1 -C 4 -alkanesulsulfonyl halide such as methanesulfonyl chloride, methanesulfonyl bromide, ethanesulfonyl chloride and butanesulfonyl chloride; C 8 -C 8 -aryl halides such as benzenesulfonyl chloride, p-toluenesulfonyl chloride, p-toluenesulfonyl chloride) or C 1 -C 4 -alkanesulfonanhydrides such as methanesulfonic anhydride, ethanesulfonic anhydride and butanesulfonic anhydride, preferably methanesulfonyl chloride, ethanesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride or methanesulfonic acid anhydride and particularly preferably C 1 to C 20 methanesulfonyl chloride. at room temperature) for 30 minutes to 24 hours (preferably 1 hour to 10 hours) in an inert solvent (e.g. hydrocarbons such as hexane, cyclohexane, benzene, toluene and xylene; halogenated hydrocarbons such as dichloromethane, 2-dichloroethane and carbon tetrachloride or ethers such as ether, tetrahydrofuran and dioxane; or nitriles such as acetonitrile, preferably at least one or more nitriles such as acetonitrile, preferably at least one of the nitriles such as acetonitrile. nitriles and particularly preferably acetonitrile) in the presence or absence of a base (for example, organic amines such as triethylamine, N-methylmorpholine, pyridine and 4-dimethylaminopyridine and preferably triethylamine) to prepare the sulfonyloxy compound and then reacting the sulfonyloxy compound with tetra (C 1 -C 4 - alkyl) ammonium nitrate (e.g. tetramethylammonium nitrate, tetraethylammonium nitrate or tetrabutylammonium nitrate and preferably tetrabutylammonium nitrate at 0 ° C to 200 ° C (preferably 50 ° C to 150 ° C) for 30 minutes to 24 hours (preferably 1 hour to 10 hours) in an inert solvent (e.g. hydrocarbons such as benzene, toluene and xylene and preferably toluene).

After completion of the reaction, the desired compound of these reactions is captured from the reaction mixture by conventional means. For example, the desired compound from these reactions can be obtained by trapping the precipitated crystals by filtration; distilling off the solvent; or by appropriately distilling off the solvent, adding water to the reaction mixture, extracting the mixture with a water immiscible organic solvent such as ethyl acetate, drying the organic layer and evaporating the extraction solvent. If desired, the compound thus obtained can be further purified by conventional methods, for example, recrystallization, column chromatography and the like.

Method C is another method of preparing a compound of Formula I.

In step C1 a compound of formula VIII is prepared and the step is carried out by reacting a compound of formula VII or a reactive derivative thereof with a compound of formula V, in an inert solvent. This step is carried out, for example, by the halide acid method, the mixed acid anhydride method by the active ester method or by the condensation method, and is carried out in the same manner as step A1 in the aforementioned method A.

In Step C2, a compound of Formula IX is prepared and is carried out by reacting a compound of Formula VII with a nitrating agent in the absence or presence of an inert solvent. This step is carried out in the same manner as step B2 in method B above.

In step C3 a compound of formula I is prepared and the step is carried out by eliminating the mercapto protecting group and the amino protecting group of the compound of formula IX and then reacting the resulting compound with carbonyl compounds such as carbonyldiimidazole; phosgene derivatives such as phosgene and triphosgene; C 1 -C 4 -alkyl halocarbonates such as methyl chlorocarbonate, ethyl chlorocarbonate, ethyl bromocarbonate, propyl chlorocarbonate and butyl chlorohydrate; and phenyl halocarbonate derivatives such as phenyl chlorocarbonate, phenyl bromocarbonate, tolyl chlorocarbonate, methoxyphenyl chlorocarbonate and chlorophenyl chlorocarbonate (preferably carbonyldiimidazole, phosgene, triphosgene, methylchlorocarbonate, ethylchlorocarbonate, ethyl bromocarbonate or phenylchlorocarbonate).

The reaction to eliminate the mercapto protecting group and the amino protecting group is carried out by methods known in the art of synthetic organic chemistry. For example, the mercapto protecting group and the amino protecting group are eliminated by reacting the corresponding compound with an acid in an inert solvent.

Acids useful herein may include, for example, mineral acids such as hydrochloric acid, nitric acid, and sulfuric acid; carboxylic acids such as acetic acid and trifluoroacetic acid; and sulfonic acids such as methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid, preferably hydrochloric acid, trifluoroacetic acid or p-toluenesulfonic acid, and particularly preferably hydrochloric acid.

The inert solvent useful herein is not particularly limited insofar as it does not affect the reaction and may include, for example, hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane and carbon tetrachloride; ethers such as ether, tetrahydrofuran and dioxane; ketones such as acetone; and nitriles such as acetonitrile, preferably halogenated hydrocarbons or ethers, and particularly preferably ethers.

The reaction temperature varies depending on the starting material, etc., and is usually -20 ° C to 50 ° C, and preferably room temperature. The reaction time varies depending on the reaction temperature, etc., and is usually 30 minutes to 24 hours (preferably 1 hour to 10 hours).

When the mercapto protecting group and / or the amino protecting group is a trisubstituted silyl group, the protecting group is also eliminated by reacting the corresponding compound with a reagent that produces a fluorine anion such as tetraammonium fluoride and potassium fluoride instead of an acid.

The mercapto protecting group and the amino protecting group may be eliminated in sequence and preferably eliminated simultaneously and under the same conditions.

The reaction of the compound obtained by eliminating the mercapto protecting group and the amino protecting group with the carbonyl compound is preferably carried out in an inert solvent.

The inert solvent useful herein is not particularly limited insofar as it does not affect the reaction and may include, for example, hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane and carbon tetrachloride; ethers such as ether, tetrahydrofuran and dioxane; ketones such as acetone; and nitriles such as acetonitrile, preferably halogenated hydrocarbons or ethers, and particularly preferably halogenated hydrocarbons.

The reaction temperature varies depending on the starting material, etc., and is usually -20 ° C to 50 ° C, and preferably room temperature. The reaction time varies depending on the reaction temperature, etc., and is usually 10 minutes to 10 hours (preferably 20 minutes to 5 hours).

After completion of the reaction, the desired compound of these reactions is captured from the reaction mixture by conventional means. For example, the desired compound from these reactions can be obtained by distilling off the solvent; or by appropriately distilling off the solvent, adding water to the reaction mixture, extracting the mixture with a water immiscible organic solvent such as ethyl acetate, drying the organic layer and evaporating the extraction solvent. If desired, the compound thus obtained can be further purified by conventional methods, for example, recrystallization, column chromatography and the like.

The starting compound of formula (VII) for Method C is known or is readily prepared by known methods or methods similar to them [e.g., Chem. Absts., 74, 100379b (1971)].

The compound of the formula (Γ) also has an excellent anti-ulcer effect and is prepared in the same manner as in the above procedures using a compound of the formula IV 'instead of a compound of formula IV or a compound of formula V' instead of a compound of formula V.

CONH '( ^R ) ^x (CH ₂ ) _n -ONO ₂ (I') · 9 9 ············

41 R ² H ₂ N 4 (CH ₂ ) _n -ONO ₂ (IV ') R ² H.sub.2CH.sub.3 -OH (IN')

In the above formulas, R1, R2 and ^{n have the} same meanings as defined above.

The compound of formula (II), which is an active ingredient of the preventive or ulcer therapeutic agent of the present invention, is a known compound or is readily prepared by conventional procedures (e.g. Japanese Unexamined Patent Publication (KOKAI) No. Hei 5-213910 etc.)

Effects of the invention

The compound of the formula I according to the invention has a strong effect on the collateral blood vessel stretching, has low toxicity and few side effects such as headache, dizziness, cardiac acceleration or harmful effects on the digestive system, liver, bones etc. and does not undergo the initial release of passage and is useful as a preventive agent and as a therapeutic agent (preferably a therapeutic agent) for angina pectoris.

At the same time, the compound of formula (II) or a pharmacologically acceptable salt thereof has a strong anti-ulcer effect, poor toxicity and fewer side effects such as headache, dizziness, cardiac acceleration or gastrointestinal, liver, bone, etc. effects and is useful as a preventive agent; as a therapeutic agent (preferably a therapeutic agent) for ulcer disease.

The compound has excellent storage stability and is easy to handle.

Industrial Applicability • ·

• · · · · · · · · · · · · · · · · · · · · · ·

When a compound of formula (I) of the present invention is used as a therapeutic agent or as a preventive agent for angina pectoris; or a compound of formula II and a pharmacologically acceptable salt thereof as a preventive agent or as a therapeutic agent for ulcer, may be administered as such or in admixture, for example, with a suitable pharmacologically acceptable neutral excipient, diluent and the like in the form of a tablet, capsule , granules, powder, syrup for oral administration, and an injectable preparation for parenteral administration.

These preparations are prepared in a known manner using excipients such as excipients (for example, sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, mashed potato starch, α-starch, dextrin and carboxymethyl starch; cellulose derivatives such as is crystalline cellulose, low hydroxypropyl-substituted cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, calcium carboxylmethylcellulose and sodium carboxymethylcellulose with internal bridges; arabic gum; dextran; pullulan; silicate derivatives such as light silicic anhydride; calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate), binders (for example, the aforementioned excipients; gelatin; polyvinylpyrrolidone; and Macrogol); disintegrants (for example, the aforementioned excipients; chemically modified starch, cellulose derivatives, etc. such as Crosscarmelose sodium, sodium carboxymethyl starch and bridged polyvinylpyrrolidone), lubricants (e.g. talc; stearic acid; and metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as beeswax and spermacet; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylates such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; is silicic anhydride and silicic acid hydrate; and starch derivatives in the above excipients), stabilizers (e.g., p-hydroxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; acetic anhydride; and sorbic acid); corrigents (eg, sweeteners, acidifying agents and perfumes conventionally used), diluents and solvents for injectable agents

(e.g., water, ethanol, and glycerin). The dose varies depending on the conditions and age of the patient to be treated and is desirably administered 1 to 6 times daily depending on the conditions: in the case of oral administration, the lower limit is 1 mg always (preferably 5 mg) and the upper limit is 1000 mg for adult; and in the case of intravenous administration, a lower limit of 0.1 mg each and an upper limit of 100 mg (preferably 50 mg) for an adult.

The invention will be described more specifically below by way of examples, reference examples, test examples and formulation examples, but the invention is not limited thereto.

DETAILED DESCRIPTION OF THE INVENTION

Example 1 (4R) -N - [(1S) -1-Methyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide (Model Compound No. 1-1)

2.06 g of (4R) -2-oxothiazolidine-4-carboxylic acid are suspended in 60 ml of dry tetrahydrofuran and 2.00 g of (1S) -1-methyl-2-nitroxyethylamine hydrochloride, 4,5 g, are added under stirring with ice-cooling. ml of triethylamine and 3.00 ml of diphenylphosphoryl azide and the mixture was stirred at room temperature for 5 hours. Then, the solvent was distilled off under reduced pressure, and the residue was purified on a silica gel column using cyclohexane-ethyl acetate (1: 4) as eluent to give 3.00 g of colorless crystals. The crystals were recrystallized from ethyl acetate to give 0.964 g of the desired compound as colorless needle crystals.

Melting point: 122-123 C (dec.)

NMR spectrum (CDCl ₃ + DMSO-d ₆ ) δ ppm: 1.27 (3H, d, J = 6.6 Hz), 3.67 (2H, d, J = 6.6 Hz), 4.10- 4.57 (4H, m), 7.57 (1H, bs), 7.78 (1H, br.s)

Example 2 (4R) -N - [(1S) -1-methyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide (Model Compound No. 1-1) • 4 (2a) (4R) -N - [(1S) -1-methyl-2-hydroxyethyl] -2-oxothiazolidin-4-ylcarboxamide

1.0 g of (4R) -2-oxothiazolidine-4-carboxylic acid are dissolved in 20 ml of dry tetrahydrofuran and 0.56 g of L-alaninol, 2.8 ml of triethylamine and 1.8 ml of diphenylphosphoryl azide are added under ice-cooling. and the mixture was stirred at room temperature for 3 hours. Then, the solvent was distilled off under reduced pressure, and the residue was purified on a silica gel chromatography column using dichloromethane-methanol (95: 5) as eluent to give 0.92 g of the desired compound as colorless crystals.

Melting point: 160-162 C

NMR spectrum (DMSO-d6) δ ppm: 1.04 (3H, d, J = 6.7 Hz), 3.20-3.40 (3H, m), 3.63 (1H, dd, J = 8) 6 Hz, J = 11.2 Hz), 3.70-3.88 (1H, m), 4.16-4.22 (1H, m), 4.73 (1H, t, J = 5, 6 Hz), 7.83 (1H, d, J = 7.9Hz), 8.24 (1H, bs) (2b) (4R) -N - [(1S) -1-methyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide

478 mg of nitrite terafluoroborate (85% content) are dissolved in 10 ml of dry acetonitrile, and 0.43 ml of 2,4,6-collidine are added thereto under stirring with ice-cooling, and the mixture is stirred under ice-cooling for 30 minutes. 500 mg of (4R) -N - [(1S) -1-methyl-2-hydroxyethyl] -2-oxothiazolidin-4-ylcarboxamide was added to the resulting mixture, and the mixture was then stirred at room temperature for 1 hour and 45 minutes. Thereafter, the solvent was distilled off under reduced pressure, and the residue thus obtained was purified by chromatography on a silica gel column using cyclohexane ethyl acetate (3: 7) as eluent to give 178 mg of the title compound as colorless crystals. Melting point: 119-122 C (dec.)

The NMR spectrum of the compound was identical to that of Example 1.

Example 3 (4R) -N - [(1S) -1-methyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide (Model Compound No. 1-1) (3a) N - [(1S) - 1-Methyl-2-hydroxyethyl] - (2R) -2-t-butoxycarbonylamino-3-t-butoxycarbonylthiopropanamide ···· · · · ··· · · · · · · · · · · ·

5.0 g of N, S-di-t-butoxycarbonyl-L-cysteine are dissolved in 100 ml of dry tetrahydrofuran and 1.3 g of L-alaninol, 4.4 ml of triethylamine and 4.0 ml are added under stirring with ice-cooling. diphenylphosphoryl azide and the mixture was stirred at room temperature for 4 hours. Thereafter, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography using cyclohexane-ethyl acetate (1: 1) as eluent to give 3.55 g of the desired compound as colorless needle crystals.

Melting point: 70-72 C NMR spectrum (CDCl3) δ ppm: 1.19 (3H, d, J = 6.9 Hz), 1.45 (9H, s), 1.51 (9H, s), 2 , 65-2.90 (1H, bs), 3.03-3.30 (2H, m), 3.42-3.58 (IH, m), 3.63-3.78 (IH, m) 3.95-4.04 (1H, m), 4.20-4.35 (IH, m), 5.42-5.68 (IH, bm), 6.46 (IH, d, J = 7.8 Hz) (3b) N - [(1S) -1-methyl-2-nitroxyethyl] - (2R) -2-t-butoxycarbonylamino-3-t-butoxycarbonylthiopropanamide

1.24 g of nitrite terafluoroborate (85% content) was dissolved in 25 ml of dry acetonitrile, and 1.12 g of 2,4,6-collidine was added thereto under stirring with ice-cooling, and the mixture was stirred under ice-cooling for 30 minutes. A solution obtained by dissolving 2.5 g of N - [(1S) -1-methyl-2-hydroxyethyl] - (2R) -2-t-butoxycarbonylamino-3-t-butoxycarbonylthiopropanamide in 25 ml of dry acetonitrile is then added to the resulting mixture and the resulting mixture was then stirred at room temperature for 3 hours. Thereafter, the solvent was distilled off under reduced pressure, and the residue thus obtained was purified by chromatography on a silica gel column using cyclohexane ethyl acetate (4: 1) as eluent to give 1.39 g of the desired compound as pale yellow crystals. Melting point: 123-124 C (dec.)

NMR spectrum (CDCl 3) δ ppm: 1.27 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 1.51 (9H, s), 3.05-3.28 ( 2H, m), 4.20-4.55 (4H, m), 5.42 (1H, d, J = 6.3 Hz), 6.45-6.65 (1H, bs) (3c) ( 4R) -N - [(1S) -1-methyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide

Dissolve 1.0 g of N - [(1S) -1-methyl-2-nitroxyethyl] - (2R) -2-t-butoxycarbonylamino-3-t-butoxycarbonylthiopropanamide in 10 ml of a solution of 4N hydrochloric acid in dioxane and dissolve the solution at The mixture was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure. Benzene was added to the residue and the solution was evaporated to dryness under reduced pressure. The residue thus obtained is suspended in 10 ml of dry dichloromethane, to which 0.46 g of carbodiimidazole is added and the mixture is stirred at room temperature for 40 minutes. The reaction mixture was purified by silica gel column chromatography using ethyl acetate as eluent to give 0.45 g of pale yellow crystals. The crystals were recrystallized from ethyl acetate to give 84 mg of the desired compound as colorless crystals.

Melting point: 125-126 C (dec.)

The NMR spectrum of the compound was identical to that of Example 1.

Example 4 (4R) -N - [(1S) -1-ethyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide (Model Compound No. 1-15)

0.50 g of (4R) -2-oxothiazolidine-4-carboxylic acid is suspended in 10 ml of dry tetrahydrofuran, 0.70 g of (1S) -1-ethyl-2-nitroxyethylamine hydrochloride, 1.4 ml of triethylamine and 0, 62 ml of diethyl cyanophosphoric acid and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure, and the residue was purified on a silica gel column using cyclohexane-ethyl acetate (1: 2) as eluent to give a light yellow oil. Isopropyl ether was added to the oil to give a pale yellow powder. The powder was dissolved in acetone (10 ml) and ethyl acetate (5 ml) was added. The acetone was distilled off under reduced pressure and the mixture was allowed to stand at room temperature to give 0.24 g of the desired compound as colorless columnar crystals.

Melting point: 106-107 C (dec.)

NMR spectrum (d ₆ -DMSO) δ ppm: 0.87 (3H, t, J = 7.4 Hz), 1.30-1.68 (2H, m), 3.32 (1H, dd, J =

5.0 Hz, J = 11.2 Hz), 3.68 (1H, dd, J = 8.5 Hz, J = 11.2 Hz), 3.95-4.10 (1H, m), 4 25-4.35 (1 H,

m), 4.41 (1H, dd, J = 7.5Hz, J = 11.2Hz), 4.60 (1H, dd, J = 4.3Hz, J = 11.2Hz), 8 , 09 (1 H, d,

J = 8.5 Hz), 8.27 (1H, bs)

Example 5 (4R) -N - [(1S) -1-Propyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide (Model Compound No. 1-27)

0.84 g of the desired compound is obtained as colorless crystals in a similar manner to that in Example 4 using 0.50 g of (4R) -2-oxothiazolidine-4-carboxylic acid and 0.75 g of (1S) -1-propyl- Of 2-nitroxyethylamine hydrochloride.

Melting point: 99-100 C (dec.)

NMR spectrum (d 6 -DMSO) δ ppm: 0.87 (3H, t, J = 7.1 Hz), 1.15-1.55 (4H, m), 3.32 (1H, dd, J = 4) 8 Hz, J = 11.2 Hz), 3.68 (1H, dd, J = 8.6 Hz, J = 11.2 Hz), 4.03-4.18 (1H, m), 4, 23-4.33 (1H, m), 4.39 (1H, dd, J = 7.5Hz, J = 11.2Hz), 4.60 (1H, dd, J = 4.2Hz, J = 11.2 Hz], 8.09 (1H, d, J = 8.5Hz), 8.27 (1H, bs)

Example 6 (4R) -N - [(1S) -1-Butyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide (Model Compound No. 1-71)

570 mg of the desired compound is obtained as colorless crystals in a similar manner to that in Example 4 using 441 mg of (4R) -2-oxothiazolidine-4-carboxylic acid and 500 mg of (1S) -1-butyl-2-nitroxyethylamine hydrochloride.

Melting point: 110-112 C (dec.)

NMR spectrum (d ₆ -DMSO) δ ppm: 0.91 (3H, t, J = 7.2 Hz), 1.20-1.43 (4H, m), 1.45-1.75 (2H, m), 3.61 (1H, dd, J = 4.9 Hz, J = 11.2 Hz), 3.83 (1H, dd, J = 8.6 Hz, J = 11.2 Hz), 4 23-4.45 (3H, m), 4.60 (1H, dd, J = 3.3Hz, J = 11.2Hz), 6.65 (1H, bs), 6.81 (1H, d, J = 8.6 Hz)

Example 7 (4R) -N - [(1S) -1-Isopropyl-2-nitroxyethyl] -2-oxothiazolidin-4-yl-carboxamide (Model Compound No. 1-59)

343 mg of the desired compound is obtained as colorless crystals in a similar manner to that in Example 4 using 333 mg of (4R) -2-oxothiazolidine-4-carboxylic acid and 500 mg of (1S) -1-isopropyl-2-nitroxyethylamine hydrochloride.

Melting point: 89-91 ° C

NMR spectrum (d 6 -DMSO) δ ppm: 0.96 (3H, d, J = 7.3 Hz), 1.00 (3H, d, J = 6.6 Hz), 1.83-2.02 ( 1H, m), 3.64 (1H, dd, J = 4.0Hz, J = 11.2Hz), 3.84 (1H, dd, J = 8.6Hz, J = 11.2Hz) 4.05-4.20 (1H, m), 4.35-4.52 (2H, m), 4.65 (1H, dd, J = 4.0 Hz, J = 11.2 Hz), 6.80 (1H, bs), 6.86 (1H, d, J 9.2 Hz)

Example 8 (4R) -N - [(1S) -1-isobutyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide (Model Compound No. 1-83)

636 mg of the desired compound is obtained as a yellow oil in a similar manner to that in Example 4 using 544 mg of (4R) -2-oxothiazolidine-4-carboxylic acid and 500 mg of (1S) -1-isobutyl-2-nitroxyethylamine hydrochloride.

NMR spectrum (d ₆ -DMSO) δ ppm: 0.93 (3H, d, J = 6.6 Hz), 0.95 (3H, d, J = 7.9 Hz), 1.30-1.80 (3H, m), 3.61 (1H, dd, J = 4.0Hz, J = 11.2Hz), 3.82 (1H, dd, J = 8.6Hz, J = 11.2Hz) 4.30-4.50 (3H, m), 4.59 (1H, dd, J = 3.3Hz, J = 11.2Hz), 6.69 (1H, bs), 6.85 (1H, d, J = 7.9Hz)

Reference Example 1 (4R) -N - [(1R) -1-methyl-2-nitroxyethyl] -2-oxothiazolidin-4-ylcarboxamide

5.64 g of (4R) -2-oxothiazolidine-4-carboxylic acid are suspended in 100 ml of dry benzene, 6.7 ml of oxalyl chloride and a few drops of dimethylformamide are added, and the mixture is stirred at room temperature for 3 hours. Thereafter, the solvent was distilled off under reduced pressure, additional benzene was added, and the suspension was azeotroped to dryness to give a pale yellow acid chloride.

• ·

• 4 · 4 · · · · · · · · · · · · · · · · ·

5.00 g of (1R) -1-methyl-2-nitroxyethylamine hydrochloride, 14 ml of triehylamine are suspended in 150 ml of dry dichloromethane and a solution of the previously obtained acid chloride dissolved in 70 ml of dry dichloromethane is added dropwise with stirring and ice-cooling. and stirred under ice-cooling for 1 hour. Thereafter, the solvent was distilled off under reduced pressure and the residue was purified on a silica gel column using cyclohexane-ethyl acetate (1: 4) as eluent to give pale yellow crystals. The crystals were recrystallized from ethyl acetate to give 2.79 g of the desired compound as colorless crystals. Melting point: 101-102 C (dec.)

NMR spectrum (CDCl 3 + d 6 -DMSO) δ ppm: 1.27 (3H, d, J = 6.9 Hz), 3.55-3.75 (2H, m), 4.234.58 (4H, m) 7.47 (1H, d, J = 7.1Hz), 7.61 (1H, s)

Reference Example 2 (1S) -N- (t-butoxycarbonyl) -1-methyl-2-nitroxyethylamine

17.9 g of nitrite terafluoroborate are suspended in 200 ml of dry acetonitrile and 17.5 ml of 2,4,6-collidine are added dropwise at -5 ° C to 0 ° C under a stream of nitrogen. The reaction mixture was stirred at 0 ° C for 30 minutes, to which was added 10.7 g of N-t-butoxycarbonyl-L-alaninol, and the mixture was stirred at room temperature for 1 hour and 20 minutes. Then the solvent was distilled off under reduced pressure and ethyl acetate was added to the residue. Insoluble materials were filtered off and the filtrate was evaporated to dryness under reduced pressure. The yellow oil thus obtained is purified by silica gel column chromatography using cyclohexane-ethyl acetate (9: 1) as eluent to give 7.12 g of the desired compound as a colorless oil.

NMR spectrum (CDCl 3) δ ppm: 1.23 (3H, d, J = 7.3 Hz), 1.45 (9H, s), 3.90-4.15 (1H, m), 4.274.75 ( 3H, m)

Reference Example 3 (1S) -1-methyl-2-nitroxyethylamine hydrochloride ··············· ·· · · · · ···

4.52 g of (1S) -N- (t-butoxycarbonyl) -1-methyl-2-nitroxyethylamine are dissolved in 80 ml of 4N hydrochloric acid in dioxane and the mixture is aged at room temperature for 1 hour and 50 minutes. Ether (160 ml) was added and the crystals were collected by filtration and dried to give 3.02 g of the desired compound as colorless crystals.

Melting point: 134-135 C NMR spectrum (CDCl 3 + d 6 -DMSO) δ ppm: 1.47 (3H, d, J = 6.6 Hz), 3.55-3.70 (1H, m), 4.654 80 (2H, m)

Reference Example 4 (1R) -N- (t-butoxycarbonyl) -1-methyl-2-nitroxyethylamine

8.55 g of the desired compound is obtained as a colorless oil by a procedure similar to that in Reference Example 3 using 13.09 g of nitrite tetrafluoroborate and 7.72 g of N-t-butoxycarbonyl-D-allanine.

NMR spectrum (CDCl 3) δ ppm: 1.23 (3H, d, J = 7.3 Hz), 1.45 (9H, s), 3.95-4.15 (1H, m), 4.284.75 ( 3H, m)

Reference Example 5 (1R) -1-Methyl-2-nitroxyethylamine hydrochloride

1.60 g of the desired compound is obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 8.55 g of (1R) -N- (t-butoxycarbonyl) -1-methyl-2-nitroxyethylamine and 90 ml of 4N hydrochloric acid in dioxane.

Melting point: 133-135 C

NMR spectrum (CDCl ₃ + DMSO-d ₆ ) δ ppm: 1.47 (3H, d, J = 6.9 Hz), 3.55-3.70 (1H, m), 4.654.78 (2H, m) )

Reference Example 6 - (1S) -N- (t-butoxycarbonyl) -1-ethyl-2-nitroxyethylamine

3.19 g of the desired compound is obtained as a pale yellow oil by a procedure similar to that in Reference Example 2 using 4.00 g of nitrite tetrafluoroborate and 4.03 g of (1S) -N-t-butoxycarbonyl-1-ethyl-2-hydroxyethylamine.

NMR spectrum (CDCl 3) δ ppm: 0.98 (3H, t, J = 7.3 Hz), 1.40-1.70 (2H, m), 1.45 (9H, s), 3,703.95 ( 1H, m), 4.20-4.70 (3H, m)

Reference Example 7 (1S) -1-ethyl-2-nitroxyethylamine hydrochloride

2.10 g of the desired compound is obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 3.19 g of (1S) -N- (t-butoxycarbonyl) -1-ethyl-2-nitroxyethylamine and 50 ml of 4N hydrochloric acid in dioxane.

Melting point: 121-123 C (dec.)

NMR spectrum (d ₆ -DMSO) δ ppm: 0.96 (3H, t, J = 7.2 Hz), 1.50-1.80 (2H, m), 3.35-3.50 (1H, m), 4.66 (1H, dd, J = 6.6Hz, J = 11.9Hz), 4.81 (1H, dd, J = 4.0Hz, J = 11.9Hz), 8 .49 (3H, bs)

Reference Example 8 (1S) -N- (t-butoxycarbonyl) -1-propyl-2-nitroxyethylamine

3.03 g of the desired compound is obtained as colorless crystals by a procedure similar to that in Reference Example 2 using 8.60 g of nitrite tetrafluoroborate and

7.49 g of (1S) -N- (t-butoxycarbonyl) -1-propyl-2-hydroxyethylamine.

Melting point: 57-58 ° C

NMR spectrum (CDCl 3) δ ppm: 0.95 (3H, t, J = 7.0 Hz), 1.25-1.70 (4H, m), 1.45 (9H, s), 3.804.05 ( 1H, m), 4.20-4.70 (3H, m)

Reference Example 9 (1S) -1-Propyl-2-nitroxyethylamine hydrochloride Reference Example 9 (1S) -1-propyl-2-nitroxyethylamine hydrochloride

2.77 g of the title compound are obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 4.00 g of (1S) -N- (t-butoxycarbonyl) -1-propyl-2-nitroxyethylamine and 40 ml of 4N hydrochloric acid in dioxane.

Melting point: 157-158 C (dec.)

NMR spectrum (d ₆ -DMSO) δ ppm: 0.89 (3H, t, J = 7.2 Hz), 1.30-1.70 (4H, m), 3.40-3.55 (1H, m), 4.65 (1H, dd, J = 6.8Hz, J = 11.9Hz), 4.81 (1H, dd, J = 3.4Hz, J = 11.9Hz), 8 .51 (3H, bs)

Reference Example 10 (1S) -N- (t-butoxycarbonyl) -1-butyl-2-nitroxyethylamine

1.56 g of the desired compound is obtained as a yellow oil by a procedure similar to that in Reference Example 2 using 1.87 g of nitrite tetrafluoroborate and 2.09 g of (1S) -N- (t-butoxycarbonyl) -1-butyl- Of 2-hydroxyethylamine.

NMR spectrum (CDCl ₃ ) δ ppm: 0.91 (3H, t, J = 7.3 Hz), 1.25-1.65 (6H, m), 1.45 (9H, s), 3.833.98 (1H, m), 4.30-4.60 (3H, m)

Reference Example 11 (1S) -1-Butyl-2-nitroxyethylamine hydrochloride

702 mg of the desired compound is obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 1.56 g of (1S) -N- (t-butoxycarbonyl) -1-butyl-2-nitroxyethylamine and 15 ml of 4N hydrochloric acid. in dioxane.

Melting point: 133-135 C (dec.)

NMR spectrum (CDCl 3) δ ppm: 0.94 (3H, t, J = 7.3 Hz), 1.20-2.00 (6H, m), 3.55-3.70 (1H, m),

4.65-4.85 (2 H, m)

Reference Example 12 (1S) -N- (t-butoxycarbonyl) -1-isopropyl-2-nitroxyethylamine

3.07 g of the desired compound is obtained as a yellow oil by a procedure similar to that in Reference Example 2 using 3.19 g of nitrite tetrafluoroborate and 3.31 g of (1S) -N- (t-butoxycarbonyl) -1-isopropyl- Of 2-hydroxyethylamine.

NMR spectrum (CDCl 3) δ ppm: 0.97 (3H, d, J = 5.9 Hz), 0.99 (3H, d, J = 6.6 Hz), 1.45 (9H, s), 3 65.3.80 (1 H, m), 4.35-4.63 (3 H, m)

Reference Example 13 (1S) -1-Isopropyl-2-nitroxyethylamine hydrochloride

1.97 g of the desired compound is obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 3.07 g of (1S) -N- (t-butoxycarbonyl) -1-isopropyl-2-nitroxyethylamine and 30 ml of 4N hydrochloric acid in dioxane.

Melting point: 174-175 C (dec.)

NMR spectrum (CDCl 3) δ ppm: 1.14 (3H, d, J = 7.3 Hz), 1.17 (3H, d, J = 6.6 Hz), 2.10-2.30 (1H, m), 3.40-3.52 (1 H, m), 4.70-4.90 (2 H, m)

Reference Example 14 (1S) -N- (t-butoxycarbonyl) -1-isobutyl-2-nitroxyethylamine

3.84 g of the title compound are obtained as a yellow oil by a procedure similar to that in Reference Example 2 using 3.91 g of nitrite tetrafluoroborate and 4.35 g of (1S) -N- (t-butoxycarbonyl) -1-isobutyl. -2-hydroxyethylamine.

NMR spectrum (CDCl 3) δ ppm: 0.93 (3H, d, J = 4.6 Hz), 0.95 (3H, d, J = 4.6 Hz), 1.20-1.50 (2H, m), 1.45 (9H, s), 1.60-1.80 (1H, m), 3.90-4.10 (1H, m), 4.25-4.65 (3H, m)

Reference Example 15 (1S) -1-isobutyl-2-nitroxyethylamine hydrochloride * in * ·············

2.32 g of the title compound are obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 3.84 g of (1S) -N- (t-butoxycarbonyl) -1-isobutyl-2-nitroxyethylamine and 40 ml of 4N hydrochloric acid in dioxane.

Melting point: 174-175 C (dec.)

NMR spectrum (CDCl ₃ ) δ ppm: 0.93-1.10 (6H, m), 1.50-1.70 (1H, m), 1.72-2.00 (2H, m), 3, 65-3.82 (1 H, m,), 4.63-4.85 (2 H, m)

Reference Example 15 (1S) -1-isobutyl-2-nitroxyethylamine hydrochloride

2.32 g of the title compound are obtained as colorless crystals by a procedure similar to that in Reference Example 3 using 3.84 g of (1S) -N- (t-butoxycarbonyl) -1-isobutyl-2-nitroxyethylamine and 40 ml of 4N hydrochloric acid in dioxane.

Melting point: 174-175 C (dec.)

NMR spectrum (CDCl 3) δ ppm: 0.93-1.10 (6H, m), 1.50-1.70 (1H, m), 1.72-2.00 (2H, m), 3,653.82 (1H, m,), 4.63-4.85 (2H, m)

Test Example 1

Effect on the expansion of collateral vessels by intravenous administration

Dogs (beagle, male) weighing 9-13 kg were anesthetized by intravenous injection of pentobarbital 30 mg / kg and tested under artificial respiration. To measure left carotid artery pressure, a polyethylene cannula (Atom intravenous cather 2F) was antegradially inserted into one branch of the left thyroid artery. The left ascending carotid artery current from this pressure measurement site was occluded by a vascular clip for 1 minute and the pressure immediately prior to occlusion (P) and peripheral pressure reduction (ΔΡ) was measured. Then, another drug was injected into the inguinal vein via another polyethylene cannula. The left carotid artery was occluded for 1 minute after 5, 15, 30, 45 and 60 minutes and each time the pressure immediately prior to occlusion (Pa) and the peripheral pressure reduction was measured.

4 4 4 4 • 4 * 4 · 4 ·· (APa). The Collateral Index (Cl) effect of the test drug was determined using the following formula:

Cl = 100- (APa / Pa) x100 / (ΔΡ / Ρ)

As a result of this test, the compounds of Examples 1, 5, 6 and 8 show an excellent effect when Cl (60) at a dose of 0.3 mg / kg is greater than 10.

Test Example 2

Effect on the widening of the collateral vessels when administered into the portal vein.

While test samples were prepared according to the method of Test Example 1, the animal was laparotomized on the adbominant median line and the mesenteric vein branch was removed and trimmed so that the test drug was administered into the portal vein. An intravenous polyethylene cannula (Atom intravenous catheter 2F) was inserted into this vein to rest in the portal vein and then the drug was administered. To test the effect of the initial release of test drug passage, it was first administered intravenously (inguinal vein) for 60 minutes to determine the effect on collateral blood vessel widening. The same test drug was then administered into the portal vein 2 or 3 hours later to determine the effect on collateral blood vessel widening for 60 minutes, and the effects were compared to each other.

As a result of this test, the compound of Example 1 showed an excellent effect on collateral blood vessel widening.

Test Example 3

Inhibition of aspirin-induced ulcer

The test animals used were 10 rats of Donry strain, each weighing 200 g - 250 g, per group. The rats were fasted for 24 hours but could freely drink water. Test compounds were suspended in a 0.5% carboxymethylcellulose (CMC) solution. At the same time, a 0.5% CMC solution was used for the control group.

The rats were orally administered (0.1 ml / 100 g body weight) test compound and 1 hour later the rats were orally (0.1 ml / 100 g body weight) aspirin solution.

(150 mg / ml: suspended in 0.5% CMC solution). Four hours after aspirin solution administration, rats were sacrificed using carbon dioxide gas and their stomachs were removed. 10 ml of 1% formalin solution was poured into the stomachs to expand the stomach and the stomachs were immersed in a beaker of 1% formalin solution for 15-20 minutes. Thereafter, each of the stomachs was slit along its larger curvature, and the area of ulceration in the gastric mucosa was measured using an imaging analyzer [Luzex-F, Nireko Co., Ltd.J. The mean value of the ulcer area of each group was calculated from the ulcer area of each rat and the inhibition rate was obtained by comparing the average value of the test group with the average value of the control group. The results are shown in Table 4.

Table 4

compound dose administered (mg / kg) Inhibition rate (° / merge from Example 1 30 63.58 *) 100 ALIGN! 80.15 **) 300 93.17 **)

*) p <0.05 **) p <0.005

According to this test, the compound of Example 1 shows an excellent anti-ulcer effect.

Test Example 4

Stability of compound

About 2 mg of the compound was accurately weighed and placed in a brown bottle. The bottle was left to stand in a dark place at room temperature (24-26 C) for weeks and the residual ratio (%) of the test compound was measured by high pressure liquid chromatography (column: Inertsil ODS-3, eluting). · Solvent: 10 nM (pH) = 7.0) phosphoric acid / acetonitrile buffer = 80/20). The results are shown in Table 5.

Table 5

compound residual ratio (%) the compound of Example 1 101.2 Compound A *) 49.8 **) *) a 1: 1 mixture of the compound of Example 1 and its (4R), (1R) -isomer **) The compound of Example 1 / its (4R), (1R) -isomer = 2/1 In this example, the compound of Example 1 showed excellent storage stability compared to the stability of a 1: 1 mixture of the compound of Example 1 and its (4R), (1R) -isomer. At the same time, the compound of Example 1 showed excellent storage stability as compared to the (4R), (1R) -isomer. Preparation Example 1 Capsule the compound of Example 1 lactose cornstarch magnesium stearate 50.0 mg 128.7 70.0 1.3

250 mg

· »·

The powder of this composition is mixed and sieved through a 60 mesh screen and then filled (250 mg per capsule) into No. 3 gelatin capsule.

Preparation example 2

Tablets

the compound of Example 1 50.0 mg lactose 124.0 cornstarch 25.0 magnesium stearate 1.0

200 mg

The powder of this composition is mixed and compressed on a tablet machine to a 200 mg tablet.

If desired, a sugar coating may be applied to the tablets.

Claims (24)

PATENT CLAIMS Use of a thia- or oxazolidinone derivative of the general formula II R (II) CO-N-A-ONO2 where W is sulfur or oxygen and X is -N (R ³ ) or X is sulfur or oxygen and W is -N (R ³ ) -; R ³ represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, or an aryl group as defined below; and R 5 are the same or different and represent a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, an aralkyl group wherein the alkyl group has from 1 to 4 carbon atoms and the aryl group is defined below, the aryl group as defined below, a five- or six-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, which may preferably be fused to a benzene ring or a five- or six-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, which may be preferably substituted and preferably fused with a benzene ring, wherein the preferred substituent is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, amino groups, and amino groups; mono- or di-alkylamino groups, wherein each alkyl group It has from 1 to 6 carbon atoms; R 6 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or an aralkyl group wherein the alkyl group has from 1 to 4 carbon atoms and the aryl group is defined below; A represents an alkylene group having from 2 to 6 carbon atoms and which is unsubstituted or substituted by a substituent selected from the group consisting of carboxyl groups, alkoxycarbonyl groups, wherein alkoxy groups have from 1 to 6 carbon atoms and aryloxycarbonyl groups, wherein the aryl group is defined below; the above aryl groups have from 6 to 10 carbon atoms and are unsubstituted or substituted with a substituent selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms hydroxyl groups, halogen atoms, amino groups, mono- and di-alkylamino groups, each alkyl group having from 1 to 6 carbon atoms, and nitro groups; or a pharmacologically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of ulcer diseases. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R 3 is a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a benzyl group or a phenethyl group. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein the hydrogen atom is a methyl group or a benzyl group. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein W is a sulfur atom or an oxygen atom and X is a group -NR 6 -, wherein it is a hydrogen atom; or X is a sulfur atom and W is the group -NR 1 -, wherein R 1 is a hydrogen atom. • • • • Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein W is a sulfur atom or an oxygen atom and X is a group -NR 6 -, wherein R 3 is a hydrogen atom. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein r 4 and R ⁵ are the same or different and are hydrogen, an alkyl group having from 1 to 4 carbon atoms, a phenylalkyl group wherein the alkyl group has 1 to 4 carbon atoms. And the phenyl group is unsubstituted or substituted by a substituent selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, hydroxyl groups, atoms halogen and nitro groups, naphthylmethyl group, phenyl group which is unsubstituted or substituted by a substituent selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms , hydroxyl groups, halogen atoms and nitro groups, a naphthyl or heterocyclic group which is selected from fur yl, thienyl, pyridyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl groups which are unsubstituted or substituted by an alkyl group having from 1 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R 6 and R 6 are the same or different and are hydrogen, methyl, benzyl, which is unsubstituted or substituted with a substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine, and atoms chloro, a phenethyl group which is unsubstituted or substituted by a substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine and chlorine groups, a phenyl group which is unsubstituted or substituted A substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine, and chlorine, furyl, thienyl, or pyridyl. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R ⁴ is a hydrogen atom, a methyl group, a benzyl group which is unsubstituted or substituted with a substituent selected from the group consisting of methyl, methoxy and hydroxyl groups, or a phenyl group which is unsubstituted or substituted with a substituent which is selected from the group consisting of methyl, methoxy and hydroxyl groups; and R 8 is a hydrogen atom. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R ⁴ is hydrogen, methyl, benzyl, phenyl or methoxyphenyl; and R 6 is hydrogen. Use of a thia- or oxazolidinone derivative of the Formula II according to claim 1, wherein R ⁴ is hydrogen, methyl, benzyl or 4-methoxyphenyl; and R 8 is a hydrogen atom. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R ⁴ is a hydrogen atom and R 6 is a hydrogen atom. • · Use of a thia- or oxazolidinone derivative of the formula II according to claim 1, wherein R ⁶ is a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a benzyl group or a phenethyl group. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein R 6 is a hydrogen atom, a methyl group or a benzyl group. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein it is a hydrogen atom. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein A is an alkylene group having from 2 to 4 carbon atoms and which is unsubstituted or substituted by a carboxyl or alkoxycarbonyl group wherein the alkoxy group has from 1 to 4 carbon atoms . Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein A is an alkylene group having from 2 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein A is ethylene or 1-methylethylene. 18. Use of a thia- or oxazolidinone derivative of the Formula II according to claim 1, wherein the hydrogen atom is an alkyl group having from 1 to 4 carbon atoms or a phenethyl group; And are the same or different and are a hydrogen atom, an alkyl group having from 1 to 5 Phenyl, wherein the alkyl group has 1 to 4 carbon atoms and the phenyl group is unsubstituted or substituted by a substituent selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups which have from 1 to 4 carbon atoms, hydroxyl groups, halogen and nitro groups, naphthylmethyl, phenyl which is unsubstituted or substituted by a substituent selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms , alkoxy groups having from 1 to 4 carbon atoms, hydroxyl groups, halogen atoms and nitro groups, a naphthyl or heterocyclic group selected from furyl, thienyl, pyridyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl groups, which group is unsubstituted or substituted with an alkyl group having from 1 to 4 carbon atoms ku; R ⁶ is a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a benzyl group or a phenethyl group; and A is an alkylene group having from 2 to 4 carbon atoms and which is unsubstituted or substituted by a carboxyl group or an alkoxycarbonyl group wherein the alkoxy group has from 1 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the Formula II according to claim 1, wherein the hydrogen atom, a methyl group or a benzyl group; R ⁴ and R ⁵ are the same or different and are hydrogen, methyl, benzyl, which is unsubstituted or substituted with a substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine, and atoms chloro, a phenethyl group which is unsubstituted or substituted by a substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine and chlorine groups; a phenyl group which is unsubstituted or substituted; a substituent selected from the group consisting of methyl, methoxy, hydroxyl, fluorine and chlorine, furyl, thienyl, or pyridyl; R 6 is hydrogen, methyl or benzyl; and A is an alkylene group having from 2 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein W is a sulfur atom or an oxygen atom and X is a group -NR 6 -, wherein it is a hydrogen atom; or X is a sulfur atom and W is the group -NR 6 -, wherein it is a hydrogen atom; R ⁴ is a hydrogen atom, a methyl group, a benzyl group which is unsubstituted or substituted with a substituent selected from the group consisting of methyl, methoxy and hydroxyl groups, or a phenyl group which is unsubstituted or substituted with a substituent which is selected from the group consisting of methyl, methoxy and hydroxyl groups; R 6 is hydrogen; R6 is hydrogen; and A is an alkylene group having from 2 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the Formula II according to claim 1, wherein W is a sulfur atom or an oxygen atom and X is a group -NR 6 -, wherein it is a hydrogen atom; R ⁴ is hydrogen, methyl, benzyl, phenyl or methoxyphenyl; is hydrogen; R 6 is hydrogen; and A is an alkylene group having from 2 to 4 carbon atoms. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein W is a sulfur atom and X is a group -NR 6 -, wherein it is a hydrogen atom; • · R 4 is hydrogen, methyl, benzyl or 4-methoxyphenyl; R 8 is a hydrogen atom; R 6 is hydrogen; and A is ethylene or 1-methylethylene. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein W is sulfur and X is -NH-; r 4 is hydrogen; R 6 is hydrogen; R 6 is hydrogen; and A is ethylene or 1-methylethylene. Use of a thia- or oxazolidinone derivative of the general formula II according to claim 1, wherein the thia- or oxazolidinone derivative of the general formula II or a pharmacologically acceptable salt thereof is selected from the group consisting of: N- (2-nitroxyethyl) -2-oxothiazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -5-methyl-2-oxothiazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -5- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -5-benzyl-2-oxothiazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -2-oxothiazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -2-oxoxazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -5- (3-furyl) -2-oxoxazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -5-benzyl-2-oxoxazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -2-oxoxazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -5-methyl-2-oxothiazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -5-methyl- (4-methoxyphenyl) -2-oxothiazolidin-4-ylcarboxamide; T t t * t * * r r r * r r r t t t t t t t t t t t t t t t · t · · N- (1-methyl-2-nitroxyethyl) -5-benzyl-2-oxothiazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -5- (3-furyl) -2-oxoxazolidin-4-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -5-benzyl-2-oxoxazolidin-4-ylcarboxamide; N- (2-nitroxyethyl) -2-oxothiazolidin-5-ylcarboxamide; N- (2-nitroxyethyl) -4- (4-methoxyphenyl) -2-oxothiazolidin-5-ylcarboxamide; N- (1-methyl-2-nitroxyethyl) -2-oxothiazolidin-5-ylcarboxamide; and N- (1-methyl-2-nitroxyethyl) -4- (4-methoxyphenyl) -2-oxothiazolidin-5-ylcarboxamide and their pharmacologically acceptable salts.